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ABSTRACT
Cyclooxygenase (COX) is the key enzyme in the biosynthesis of prostaglandins
(PGs) known as pro-inflammatory mediators. COX has two isoforms: the constitutively
expressed COX-1 and the mitogen-inducible COX-2. It has been demonstrated that
COX-2 expression is selectively induced by lipopolysaccharide (LPS) treatment after
several hours in rat alveolar macrophages (Lee et al., 1992; Chanmugam et al., 1995)
and RAW 264.7 macrophages (Gang, 1996). The mitogen-activated protein kinases
[MAPKs; extracellular signal-regulated kinases (ERKs), P38, and c-jun N-terminal
kinases (JNKs)], nuclear factor kappa B (NF-kB), and Lyn kinase are known to be
activated in the early stages (within minutes) o f LPS signaling pathways. In the current
study, the mechanism of COX-2 expression induced by LPS in RAW 264.7
macrophages was examined.
To examine the involvement of MAPKs and NF-kB on COX-2 expression,
RAW 264.7 cells were treated with LPS and known activators and inhibitors of
MAPKs, NF-kB, or protein tyrosine kinases (PTKs). To examine the role of Lyn kinase
on COX-2 expression, Phoenix (<t>NX) cells, a packaging cell line, were transfected
with Flag (epitope)-tagged lyn cDNAs in the retroviral vector pBPSTRl, and the
infectious viral particles produced by transfected d>NX cells were infected to NIH/3T3
cells, a murine fibroblast cell line.
The activation o f MAPKs by known activators was insufficient to induce COX-2
expression. Partial inhibition o f LPS-induced activation o f MAPKs by PD98059 or
SB203580 resulted in partial inhibition o f COX-2 expression. Similarly, inhibition o f
LPS-induced activation o f NF-kB by Z-LLF-CHO resulted in suppression of COX-2
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expression. Both inhibition of LPS-induced activation of MAPKs and NF-kB by
Radicicol or Herbimycin A resulted in suppression o f COX-2 expression. Transfection
data lead to an observation that high COX-2 expression and PGE 2 levels can be induced
by overexpression of mutant Lyn in NIH/3T3 cells transfected with mutant lyn DNA.
This study demonstrates that COX-2 expression induced by LPS in RAW 264.7
cells appears to be mediated via rapid activation of MAPKs and NF-kB in LPS
signaling pathways.
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CHAPTER 1
INTRODUCTION
Cyclooxygenase (COX, or prostaglandin H (PGH) synthase) is the key enzyme
that catalyzes the first step of the conversion o f arachidonic acid and other related
unsaturated fatty acids to prostaglandin endoperoxide. These in turn are converted to
various prostaglandins (PGs) and thromboxanes (TXs), which exert diverse
pathophysiological actions (Merlie et al., 1988; DeWitt et a l, 1988). Two isoforms of
COX have been identified: the constitutively expressed COX-1 (DeWitt et al., 1988;
Merlie etal., 1988; Yokoyama etal., 1988; DeWitt etal., 1990; Yokoyama etal., 1989)
and the mitogen-inducible COX-2 (Kujubu et a l, 1991; Xie et al., 1991; O’Banion et
al., 1991; Hla et al., 1992; Jones et a l, 1993; Feng et al., 1993). COX-1 is
constitutively expressed in most cell types, and PGs produced by COX-1 may have
some beneficial physiological functions, such as the antithrombogenic action of
prostacyclin released by the vascular endothelium, and the cytoprotective effect of PGs
produced by the gastric mucosa (Whittle et al., 1980). On the other hand, the
expression o f COX-2 is induced following the activation o f cells by various
proinflammatory agents including cytokines (Hla et a l, 1992; Feng et a l, 1993; Feng et
al., 1995) and other mitogens (Kujubu et a l, 1991; O’Banion et al., 1991; Hla et a l,
1992). These observations suggest that COX-2 instead o f COX-1 may be responsible
for the production o f PGs involved in inflammation. It has been shown that COX-2 is
selectively expressed in LPS-stimulated rat alveolar macrophages (Lee et al., 1992;
Chanmugam et a l, 1995) and RAW 264.7 macrophages (Gang, 1996). However, the
signal transduction pathway induced by LPS that leads to the expression o f COX-2 in

1

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

macrophages is not clearly understood. The stimulation of macrophages by LPS
treatment results in activation of mitogen-activated protein kinases (MAPKs), such as
ERK-1 & ERK-2 (extracellular signal-regulated protein kinase-1 & -2, also designated
as MAPK-1 & MAPK-2), P38, and JNKs/SAPKs (c-jun N-terminal kinases/stressactivated protein kinases) (Weinstein et al., 1992; Han et al., 1993; Hambleton et al.,
1996). These MAPKs are distinguished by the sequence o f the tripeptide dual
phosphorylation motif that is required for their activation: Thr-Glu-Tyr (ERKs), ThrPro-Tyr (JNKs), and Thr-Gly-Tyr (P38 MAP kinase) (Derijard et al., 1995). ERK-1 and
ERK-2 require dual phosphorylation o f both Threonine-183 and Tyrosine-185 for
activation (Payne et al., 1991). The immediate upstream protein kinases that
phosphorylate these residues in ERK-1 and ERK-2 are MAPK Kinase-1 (the same as
MEK-1 or MKK-1) and MAPK Kinase-2 (the same as MEK-2 or MKK-2), respectively.
MEK-1 and MEK-2 possess dual specificity for the threonine and tyrosine residues in
ERK-1 and ERK-2 (Ahn et al., 1991; Seger et al., 1991; Campbell et al., 1991). The
signaling pathway o f MAPKs is one o f the major signaling pathways transmitting
signals from growth factors, hormones, and cytokines to the immediate early genes,
which are genes induced by a stimulus in the absence of de novo synthesis of proteins.
Activated MAPKs, in turn, can activate distinct transcription factors that bind c/5-acting
elements o f the immediate early genes (Karin et al., 1995).
It has been clearly demonstrated that the promoter regions o f COX-2 genes in
different species contain cis-acting elements such as CRE, AP2, SP1, and NF-IL6
(Fletcher et al., 1992; Sirois et al., 1993; Inoue et al., 1995; Yamamoto etal., 1995;
Kosaka et al., 1994) which can be transactivated by MAPK-activated transcription

2

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

factors (Davis, 1994; Karin et al., 1995). As recently as 1998, Guan et al. assumed that
the signaling pathway of MAPKs functions as an important regulator o f prostaglandin
biosynthesis. SB203580, one o f the novel classes o f cytokine-suppressive anti
inflammatory drugs (CSAID), has been shown to be an inhibitor o f LPS-stimulated
tumor necrosis factor (TNF) and interleukin-1 (IL-1) induction. SB203580 is known to
inhibit the catalytic activity of P38 MAP kinase (Lee et al., 1994). These investigators
also have implicated the role of the P38 MAP kinase and the JNK/SAPK pathway in the
regulation of cytokine production and inflammatory mediators. The inhibition of P38
MAP kinase by SC68376, another P38 MAP kinase inhibitor, inhibited cytokineinduced stimulation of COX-2 and PGE2 production, suggesting that the signaling
pathway of P38 MAP kinase is one o f the important signaling mechanisms modulating
cytokine-induced COX-2 expression and prostaglandin biosynthesis (Guan et al., 1997).
These observations serve to potentially link prostaglandin biosynthetic pathways, which
mediate inflammatory responses, with the signaling pathway of MAPKs (Guan et al.,
1998).
It has been shown that PD98059 selectively inhibits the kinase activity of MEK1 and MEK-2 (Pang et al., 1995), which are the upstream activators that phosphorylate
and activate ERK-1 and ERK-2 in most cell types. In the current study, these specific
inhibitors of MAPKs, PD98059 and SB203580, were used to determine whether LPSinduced activation o f MAPKs (particularly ERK-1, ERK-2, or P38 MAP kinase) are
involved in the expression of COX-2 in LPS-stimulated RAW 264.7 macrophages.
In macrophages, LPS treatment also results in the activation o f the nuclear
factor-kappa B (NF-kB) transcription factor, which leads to the induction o f immediate

3
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early gene expression (Baeuerle, 1991). The cw-acting NF-kB element, which is a
specific DNA sequence recognized by NF-kB transcription factor, is known to be
present in the promoter regions of the COX-2 gene (Yamamoto et al., 1995; Fletcher et
a l, 1992; Sirois et al., 1993; Inoue et al., 1995; Kosaka et al., 1994). In most resting
cells, NF-kB is retained in the cytoplasm in an inactive form because an inhibitory
protein, IkB-a, is associated with NF-kB, thereby preventing its nuclear translocation.
Certain extracellular stimuli cause degradation of IkB-a, resulting in the release of free
and active NF-kB, which translocates to the nucleus and induces gene transcription
through the cw-acting kB element in transcribed genes (Siebenlist et al., 1994). The
activation o f NF-kB correlates with rapid proteolytic degradation of IkB-a regardless of
signals or cell types (Brown et al., 1993; Sun et al., 1993). DiDonato et al. (1995) used
Vinitsky’s multicatalytic protease complex (MPC) inhibitor Z-LLF-CHO (benzyloxycarbonyl-Leu-Leu-phenylalaninal) to demonstrate that the degradation of IkB-a is
required for NF-kB activation. Using this inhibitor o f NF-kB, we examined whether
inhibition of LPS-induced NF-kB activation results in the suppression o f COX-2
expression in LPS-stimulated RAW 264.7 macrophages. This experiment reveals that
the degradation o f IkB-a induced by LPS treatment indicates NF-kB activation.
It has been suggested that protein tyrosine kinases (PTKs) might regulate cell
proliferation and differentiation (Fantl et al., 1993; Ullrich and Schlessinger, 1990).
Many growth factor receptors and oncogene products are believed to possess PTK
activity. Two types of PTKs have been identified: receptor type and non-receptor type.
PTKs o f receptor type participate in transmembrane signal transduction pathways.
PTKs o f non-receptor type participate in intracellular signal transduction pathways.

4
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PTKs of non-receptor type include Src family PTKs. So far, nine Src-family tyrosine
kinases have been identified (Src, Lyn, Fgr, Hck, Fyn, Yes, Lck, Blk, and Yrk) (Brown
and Cooper, 1996). Src family PTKs are highly homologous in structure; they all
contain an N-terminal myristylation domain, Src homology 2 (SH2) and Src homology 3
(SH3) domain, a protein kinase domains (catalytic), and a C-terminal regulatory domain
(Brown and Cooper, 1996).
Two major consensus tyrosine phosphorylation sites have been identified in Src
family PTKs: (1) the tyrosine autophosphorylation site in the protein kinase domain and
(2) the tyrosine phosphorylation site in the C-terminal regulatory domain.
Autophosphorylation on tyrosine residue in the protein kinase domain correlates with
Src PTK’s activation, while phosphorylation of tyrosine residue at the C-terminal
regulatory domain negatively suppresses their kinase activities (Cooper et al., 1986). A
C-terminal Src kinase (Csk) phosphorylates the tyrosine residue at the C-terminal
regulatory domain in several members o f the Src family tyrosine kinases and is thought
to play a critical role in negatively regulating kinase activity. Several lines of evidence
suggest that this regulation is governed by an intramolecular interaction between the
phosphorylated tyrosine residue in the C-terminal regulatory domain and the SH2
domain which stabilizes an inactive conformation o f the Src family PTKs.
Some Src family PTKs, in association with cell surface proteins, participate in
normal signaling pathways in hemopoietic cells including monocytes and macrophages
(Bolen et al., 1992). The initial interaction o f LPS with monocytes and macrophages
involves a LPS-binding protein (LBP) that binds to LPS and a receptor CD 14, which is
a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein (Han et al.,

5
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1993). Comparatively less is known about intracellular signaling events after binding o f
LPS to CD 14 (Ulevitch et al., 1995). Among 9 members o f the Src family PTKs, Lyn,
Hck, and Fgr are strong candidates for the primary signal transducers o f LPS responses
in monocytes and macrophages (Meng et al., 1997). All three o f these kinases are
rapidly activated following LPS treatment.
A portion of intracellular Lyn directly co-associates with CD 14 in human
monocytes (Stefanova et al., 1993). It has been shown that PTK inhibitors that inhibit
the expression o f COX-2 also reduce the tyrosine phosphorylation of Lyn PTK in rat
alveolar macrophages stimulated with LPS (Chanmugam et al., 1995). These
observations suggest that Src PTKs may be an upstream activator and play critical roles
in LPS-initiated or LPS/CD14-mediated signal transduction pathways, leading to the
expression of COX-2 in monocytes and macrophages. Many immediate early genes,
including the COX gene, are induced in Rous sarcoma virus (RS V)-infected chicken
embryo fibroblasts (CEFs) in which v-srcp60 (the tyrosine residue in the C-terminal
regulatory domain was mutated to phenylalanine) is constitutively expressed (Xie et al.,
1991). This suggests a critical role o f the tyrosine residue at the C-terminal regulatory
domain in negatively regulating the activity o f Src PTKs and also implies that the
expression o f many immediate early genes, including COX-2 gene, might be induced in
other cell types by a single amino acid change (the tyrosine residue in the C-terminal
regulatory domain) in other Src PTKs. In the current study, transfection using wild
(normal) and mutant (the tyrosine residue in the C-terminal regulatory domain was
mutated to phenylalanine) lyn DNA was used to examine whether overexpression of
mutant Lyn induces the expression o f COX-2 in NIH/3T3 cells.

6
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1.1. Research Objectives
The overall goal o f the research presented in this dissertation was to examine the
LPS signal transduction pathways that affect the expression of COX-2 in LPSstimulated RAW 264.7 macrophages. The specific goals are to determine whether
MAPKs, NF-kB, and Lyn kinase, which have been known to be activated in LPS
signaling pathways, are involved in the expression of COX-2. These studies were
carried out by (1) examination of whether the signaling pathway of LPS-induced
activation of MAPKs alone is sufficient to induce the expression o f COX-2 in RAW
264. 7 macrophages using known activators o f MAPKs, such as PMA, sorbitol, H2 O2 ,
or a combination of these factors; (2) examination of whether inhibition o f LPS-induced
activation o f MAPKs results in the inhibition of COX-2 expression in LPS-stimulated
RAW 264.7 macrophages by using the inhibitors o f MAPKs such as PD98059 (MEK-1
and MEK-2) or SB203580 (P38 MAP kinase); (3) examination of whether inhibition of
LPS-induced activation o f NF-kB results in the inhibition of COX-2 expression in LPSstimulated RAW 264.7 macrophages by using Z-LLF-CHO, an inhibitor o f NF-kB; (4)
examination of whether inhibition of both LPS-induced activation o f MAPKs and NFkB results in the inhibition o f COX-2 expression in LPS-stimulated RAW 264.7
macrophages by using PTK inhibitors such as Radicicol and Herbimycin A; (5)
examination of whether overexpression o f mutant Lyn can induce the expression of
COX-2 in NIH/3T3 cells, which are transfected with wild type and mutant lyn DNAs.
1.2. Review of Literature
LPS treatment results in high expression o f COX-2 mRNA and protein as well
as high production of prostaglandin E2 (PGE 2) in LPS-stimulated rat alveolar

7
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macrophages (Lee et al., 1992; Chanmugam et al., 1995) and RAW 264.7 cells (Gang,
1996). Numerous studies have shown that the mitogen-activated protein kinases
[MAPKs; extracellular signal-regulated kinases (ERKs), P38 MAP kinase, and c-Jun Nterminal kinases (JNKs)], nuclear factor-kappa B (NF-kB), and Src family protein
tyrosine kinases (PTKs) are rapidly activated in the LPS signaling pathways. In this
review, we describe COX and the biosynthesis of prostaglandins. We also discuss
MAPKs, Src family PTKs, and NF-kB transcription factor.
1.2.1. Cyclooygenase [COX, or Prostaglandin H (PGH) Synthase]
COX, which is also known as prostaglandin H (PGH) synthase, catalyzes the
first committed step in the formation of PGs and TXs from arachidonic acid, which are
released from the cell membrane phospholipids by a cytosolic phospholipase A2
(CPLA2 ). The pathway o f prostaglandin biosynthesis by COX from arachidonic acid is
illustrated in Figure 1. COX is a monomeric protein having approximately a 77-78 kDa
molecular weight and possessing two enzymatic activities: oxygenase activity and
hydroperoxidase activity. COX generally catalyzes two sequential reactions. The first
reaction is the formation o f prostaglandin G 2 (PGG2 ) derivatives (15-hydroperoxy-9a,
1la-peroxido-prostaenoic acids) from two molecules of oxygen and one molecule of
polyunsaturated fatty acids, such as 8,11,14-octadecatrienoic acid (linolenic acid, 18:3),
5,8,11,14-eicosatetraenoic acid (arachidonic acid, AA, 20:4), or 5,8,11,14,17eicosapentaenoic acid (EPA, 20:5). This bis-oxygenase activity that catalyzes PGG
formation is also referred to as the fatty acid cyclooxygenase, or simply the
cyclooxygenase (COX). The second reaction is a two-electron reduction o f the 15hydroperoxy group of PGG2 that produces the corresponding prostaglandin H2 (PGH2 )

8

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

STIMULUS
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Figure 1. The pathway of prostaglandin biosynthesis by COX from arachidonic acid
(Smith and Mamett, 1991).
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derivatives (Miyamoto et al., 1976; Ohki et al., 1979). The reductive reaction is carried
out by a hydroperoxidase activity. Monoclonal antibodies prepared against COX can
immunoprecipitate both COX and hydroperoxydase activities (Pagels et al., 1983),
indicating that both COX and hydroperoxidase activities are likely to be associated with
the same protein molecules.
There are three kinds o f COX inhibitors. The first class of COX inhibitors
inhibits the activity o f COX by reducing hydroperoxide activators or by preventing the
interaction o f hydroperoxide activators with heme. They include CN- and glutathione
(GSH) plus GSH peroxidase (Helmer et al., 1980). The second class o f COX inhibitors
includes some compounds with antioxidant activities. At high concentrations, they
appear to trap free radical intermediates generated during catalysis (Helmer et al., 1980;
Lands et al., 1982). The third class o f COX inhibitors is a large number of structurally
diverse agents that compete kinetically with fatty acid substrates. Included in this class
are various fatty acids, particularly polyunsaturated fatty acids (PUFAs) (Pace-Asciak et
al., 1968) and most nonsteroidal anti-inflammatory drugs (NSAIDs) (Flower, 1974). It
has been reported that NSAIDs have little or no effect on hydroperoxidase activities
(Egan et al., 1980; Mizuno et al., 1982). Most NSAIDs are reversible COX inhibitors.
However, in addition to a reversible competition with fatty acids for the active site of
COX, some agents irreversibly inhibit COX activity. Included in this class of
irreversible COX inhibitors are aspirin, indomethacin, flurbiprofen, and mefanamic acid
(Smith et al., 1971; Rome et al., 1975). These agents apparently act by deleterious
alterations in the structure o f COX (but not hydroperoxydase) active site. Aspirin
irreversibly inhibits COX activity by acetylation o f the Ser-530 in the COX active site,
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thereby excluding access for arachidonic acid, which is the substrate of COX (Smith,
1992). Both indomethacin and flurbiprofen irreversibly inhibit COX activity, but do not
form covalent linkages with amino acid side chains in the COX (Stanford et al., 1977).
It has been known that a unique feature o f COX is that following the conversion
o f PGG2 to PGH 2 , COX is rapidly autoinactivated, leading to dramatic reduction of
prostaglandin production (Wu et al., 1988). This suggests that stimulation of the
biosynthesis o f prostaglandins by COX stimulated with agonists is self-limiting because
of this rapid inactivation o f COX. It also has been reported that the half-life o f COX is
very short (t[/2<10 min), as estimated by in vitro (Wu et al., 1988) as well as in vivo
(Fagan et al., 1986) method. Additionally, COX shows another characteristic of
irreversible self-inactivation. It is estimated that after 1500 turnovers of product
formation, COX is irreversibly inactivated by a yet unidentified peroxide-like molecule
(Rossi et al., 1986; Endo et al., 1988). Therefore, rapid de novo synthesis of COX is
required to maintain prolonged production o f prostaglandins in cells and it may be a
most important mechanism to control prostaglandin biosynthesis (Rozengurt et al.,
1983). Based on these observations, it is possible to postulate that rapid de novo
synthesis o f COX is assumed to be the most important step in the regulation of
prostaglandin biosynthesis.
Although COX has been studied in detail, relatively little is known about the
factors that control COX expression and how the controlled expression o f COX in turn
affects the production o f prostaglandins. It has been demonstrated that increased COX
activity results in increased production o f prostaglandins in interleukin (IL)-la-treated
smooth muscle cells (SMC) (Feng et al., 1993), platelet-derived growth factor (PDGF)-
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treated 3T3 cells (Habenicht et al., 1985; Lin et al., 1989), and LPS-treated
macrophages (Lee et al., 1992; O’Sullivan et al., 1992; Chanmugam et al., 1995).
Selective inhibitors o f transcription and translation as well as posttranscriptional events
are responsible for the expression o f COX by the treatment o f IL-1 in human dermal
fibroblast (Raz et al., 1989). In some studies with cycloheximide and actinomycin D,
results have shown that the induction of COX activity involves the de novo synthesis of
COX mRNA and protein (Wu et al., 1988; Lin et al., 1989). Fagan et al. (1986)
reported that inhibitors of protein and RNA synthesis cause a rapid inhibition in
prostaglandin production at the prostaglandin synthase step. It has been demonstrated
that the treatment o f corticosteroids inhibits the production of prostaglandins by
inhibiting the expression of COX mRNA (Bailey et a l, 1985; Bailey et al., 1988; Pash
et al., 1988). Stimuli to induce de novo synthesis of COX mRNA and protein are
included: PDGF (Lin et al., 1989; Habenicht et al., 1985), epithermal growth factor
(EGF) (Pash et al., 1988), phorbol ester (Wu et al., 1988), IL-1 (Raz et al., 1988;
O’Neill et al., 1987), IL-2 (Frasier-Scott et al., 1988), cyclic AMP (cAMP) (Kusaka et
al., 1988), and LPS (Lee et al., 1992; Chanmugam et al., 1995; Gang, 1996).
Two isoforms o f COX have been identified in eukaryotes: the constitutively
expressed COX-1 (DeWitt et al., 1988; Merlie etal., 1988; Yokoyama et a l, 1988;
DeWitt et al., 1990; Yokoyama et al., 1989), which is encoded by a 2.8-kilobase (kb)
mRNA, and the mitogen-inducible COX-2 (Kujubu et al., 1991; Xie et al., 1991;
O’Banion et al., 1992; Hla et al., 1992; Jones et al., 1993; Feng et al., 1993), which is
encoded by a 4.0-kb mRNA. cDNAs coding for COX-1 have been cloned from ovine
(DeWitt et al., 1988; Yokoyama et al., 1988), mouse (DeWitt et al., 1990), rat (Feng et
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al., 1993; Kennedy et a l, 1993), and human (Funk et al., 1991; Hla et al., 1992;
Yokoyama et al., 1989). cDNAs coding for COX-2 have been cloned from mouse (Xie
et al., 1991; Kujubu et al., 1991), rat (Feng et al., 1993; Kennedy et al., 1993), and
humans (Hla et al., 1992). COX-1 is expressed in most type of cells. In contrast, COX2 is only detectable in prostate, brain, testis, and lung. COX-2 gene expression can be
dramatically increased in some tissues during inflammation, or in fibroblasts and
endothelial cells exposed to mitogenic stimuli (Kujubu et a l, 1992).
Xie et al. (1991) found that a mitogen-inducible COX-2 is encoded by a CEF
(chicken embryo fibroblast)-147 cDNA and the 70-kDa polypeptide is homolous with
about 59% identity to that of ovine, murine, and human COX. It also has been shown
that a 4.5-kb PMA-inducible immediate early gene transcript, termed TIS10, is
contained in PMA-treated 3T3 cells (Kujubu et a l, 1991). The murine TIS10
polypeptide possesses significant sequence identity (about 59%) to the known COX-1,
but it shows about 82% homologous to the chicken COX-2 polypeptide. A human
COX-2 cDNA also has been cloned from human umbilical vein endothelial cells (Hla et
a l, 1992). This human COX-2 cDNA encodes a polypeptide of 604 amino acids that is
about 61% homolous to the human COX-1 polypeptide.
Structurally, COX-2 protein contains more 18 amino acids very near the Cterminus o f the enzyme, which is not contained in the COX-1 protein, indicating that
COX is encoded by at least two genes that are differentially expressed and regulated in a
variety o f cell types.
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1.2.2. Biosynthesis of Prostaglandins
Prostaglandins are derived from mainly arachidonic acid (20:4, n-6) or its
precursor linoleic acid (18:2, n-6) (Willis, 1981). A process of chain elongation and
desaturation of precursor fatty acids necessary for prostaglandin biosynthesis is
summarized in Figure 2. In animals, this bioconversion takes place primarily in the
liver by several stages of chain elongation and desaturation. In the n-6 series, linoleic
acid (18:2, n-6) is desaturated to 18:3 (n-6), then elongated and desaturated to 20:3 (n-6)
and 20:4 (n-6) which are incorporated into the cell membrane phospholipids. In the n-3
series, linolenic acid (18:3, n-3) is desaturated to 18:4 (n-3), then elongated to 20:4 (n3), and further desaturated to 20:5 (n-3), which is a relatively poor substrate for
prostaglandin biosynthesis (Willis, 1981).
Arachidonic acid (AA) is predominant in cell membrane phospholipids. Stossel
et al. (1974) reported that AA is the major polyunsaturated fatty acid (PUFA) in the cell
membrane phospholipids of human monocytes and lymphocytes and comprises about
20% o f the total fatty acids. For the prostaglandin biosynthesis, AA should be
hydrolyzed by specific phospholipases from the cell membrane phospholipids (Brown et
al., 1988). After AA is released by phospholipases (e.g. cPLA2) from the cell
membrane phospholipids, AA is converted by the COX and LOX pathways to various
eicosanoids. These pathways are usually called as the AA cascades. These AA
cascades are illustrated in Figure 3. The products of the COX pathway include
thromboxanes (TXs), prostacyclins (PGIs), and prostaglandins (PGs). Among PGs,
PGEi and PGE2 are implicated in the inhibition o f various aspects of immune response,
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Figure 2. A process o f chain elongation and desaturation o f precursor fatty acids
for prostaglandin biosynthesis (Hwang, 1989).
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Figure 3. The arachidonic acid cascades (modified from Smith, 1992).
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such as lymphocyte proliferation (Goodwin et al., 1977), macrophage collagenase
synthesis (Wahl et al., 1977), and natural killer cell activity (Brunda et al., 1980).
Therefore, PGs may play a role as a mediator of a feedback mechanism for controlling
some aspects o f cell mediated immune responses (Gordon et al., 1976). TXs act as
potent platelet aggregators as well as important mediators in muscle contraction and
lipolysis (Hamberg et al., 1974). In contrast, LOX oxygenates AA to make the
hydroperoxide intermediate hydroperoxy-5, 8,12,14-eicosatetraenoic acid (HPETE),
which is further metabolized to various hydroxyeicosatetraenoic acids (HETEs) and
leukotriens (LTs). LTs have important pro-inflammatory effects and play a crucial role
in hypersensitivity reactions (Lewis et al., 1980) and bronchospasms in allergic asthma
(Dahlen etal., 1983).
1.2.3. Mitogen-Activated Protein Kinases (MAPKs)
Protein phosphorylation plays a critical role in regulating many cellular
processes in eukaryotes. In particular, protein phosphorylation is a major event of signal
transduction pathways. Processes that are reversibly controlled by protein
phosphorylation require not only protein kinases (PKs) but also protein phosphatases
(PPs). Target proteins are phosphorylated at specific sites by one or more PKs, and
these phosphates are removed by specific PPs. In principle, changing the activity o f the
cognate PK or PP or both can control the degree o f phosphorylation at specific sites
(Hunter, 1995). The latest estimate is that there are as many as 2,000 conventional PK
genes in human (Hunter, 1994). It also has been estimated that humans could have as
many as 1,000 PP genes (Hunter, 1995).
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Among PKs, mitogen-activated protein kinases (MAPKs) are sereine/threonine
kinases that are rapidly activated in cells stimulated by several extracellular agents.
MAPKs play important roles in many intracellular signal transduction pathways that
lead to gene expression (Karin et al., 1995). The MAPK pathway is known to be a
conserved eukaryotic signaling pathway that converts receptor signals into a variety of
outputs (Davis, 1994). The MAPK pathway is extensively used for the transcytoplasmic
signaling to the nucleus, where transcription o f specific genes is induced through
phosphorylation and activation o f many transcription factors catalyzed by activated
MAPKs (Hunter, 1995). The general MAPKs signaling pathway from extracellular
stimuli to the nucleus is displayed in Figure 4.
In general, a variety of extracellular stimuli lead to the formation of membraneassociated signaling complexes that deliver the signal via Ras to a protein kinase
network involving the Raf-1 kinase, the MAPK activator MEK (or MAPKK), and
MAPKs (Blenis, 1993). Activated Raf-1 in turn phosphorylates and activates MEK in
vivo and in vitro (Howe et al. 1992; Kyriakis et al., 1992). These kinases are arranged
in a linear cascade, in which Raf-1 phosphorylates and activates MEK, which in turn
phosphorylates and activates MAPKs. Activated MAPKs deliver the signal to the
nucleus, where they phosphorylate and activate specific transcriptional factors capable
o f inducing specific immediate early gene expressions (Gille et al., 1992; Hipskind et
al., 1994; Janknecht et al., 1993). There are three main classes o f MAP kinase
recognized in mammals. In addition to the classic MAP kinase, also known as the
extracellular signal-regulated protein kinase (ERK), two other distinct classes of MAP
kinases have been identified: the c-junN-tenninal kinase/stress-activated protein
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kinases (JNKs/SAPKs) (Cooper, 1994; Kyriakis et a l, 1994; Sanchez et al., 1994;
Derijard et al., 1995; Lin et al., 1995; Gupta et al., 1996) and the P38/reactivating
kinases (RK)/cytokine-suppressive binding protein (CSBP)/HOGl MAP kinase
(Freshney et al., 1994; Han et al., 1994; Lee et al., 1994; Rouse et al., 1994).
All these MAP kinases are activated by dual phosphorylation of threonine
(Thr)/tyrosine (Tyr) residues in the activation loop catalyzed by specific MAP kinase
kinases (MEK1, MEK2, SEK1/MKK4/JNKK, MKK3, MKK6/MEK6) (Cooper etal.,
1994; Han et al., 1996; Cano et al., 1995; Lin et al., 1995; Derijard et al., 1995;
Moriguchi et al., 1996; Stein et al., 1996). The activated MAP kinases in turn
phosphorylate various intracellular target proteins at Ser/Thr-Pro sequence. Although
these MAP kinases have similar primary structures, activation mechanisms, and similar
minimal consensus sequences for substrate recognition, these distinct classes of MAPK.
are differentially activated by different extracellular stimuli, and these activated MAPKs
in turn activate shared or specific downstream targets, such as many transcription
factors (Fukunaga et al., 1997).
I.2.3.I. ERK/MAP Kinases
The first o f the ERK/MAP kinases to be cloned was ERK-1 (the same as MAPK1) and ERK-2 (the same as MAPK-2) (Boulton et al., 1991a; Gotoh et al., 1991). Other
related ERK/MAP kinases have been identified including: two ERK-3 isoforms
(Gonzalez et al., 1992; Zhu et al., 1994), ERK-4 (Boulton et al., 1991b), ERK-5 (Zhou
et a l, 1995; Kato et a l, 1997; English et a l, 1998), ERK-6, and ERK-7. These
ERK/MAP kinases are activated in cells stimulated by various extracellular stimuli, such
as phorbol esters, which activate protein kinase C (PKC) and by growth factors, such as
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epithermal growth factor (EGF) and platelet-derived growth factor (PDGF), which
activate receptor protein-tyrosine kinases. These receptor protein-tyrosine kinases
activated by growth factors sequentially leads to the activation of Ras, Raf, MEK, and
ERK-1 and ERK-2 MAP kinases (Davis, 1993).
The ERK-1 and ERK-2 are activated by dual phosphorylation at Thr and Tyr
residues by MEK-1 and MEK-2, respectively (Crews et al., 1992; Ahn et al., 1992).
Several substrate proteins identified as physiological targets for ERK MAP kinases
include the 90 kDa ribosomal S6 protein kinase (called RSK), cytosolic phospholipase
A2 (called CPLA2 ), and transcriptional factors, such as Elk-1 (Davis, 1993; Janknecht et
al., 1993; Marais et al., 1993; Gille et al., 1995). It has been recently demonstrated that
three p90 ribosomal S6 kinase (RSK) isozymes (RSK1, RSK2, and RSK3) interact with
extracellular signal-regulated kinase (ERK) but not c-Jun-NH2-kinase (JNK) or p38
mitogen-activated protein kinase (MAPK) (Smith et al., 1999). These observations
suggest that activated ERK MAPKs play a role in gene expression.
1.23.2. P38/HOG1 MAP Kinase (or RK/CSBP)
P38/HOG1 MAP kinases are stress-responsive MAP kinases. In yeast, HOG1 is
necessary for growth in conditions o f high osmolarity, but not required for normal
growth (Brewster et al., 1993). In mammalian cells, P38 MAP kinase, a HOG1
homologue, responds to extracellular stimuli, such as heat, chemical stress, high
osmolarity, LPS (Han etal., 1994), andIL-1 (Freshney etal., 1994). BothHOGl and
P38 MAP kinase share the parallel MAPKK-like activation motif Thr-Gly-Tyr rather
than Thr-Glu-Tyr found in ERK-1 and ERK-2 or Thr-Pro-Tyr found in JNKs, suggesting
activation by an alternative MAPKK (Lee et al., 1994). P38 has been implicated to be a
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crucial MAPK. in the pro-inflammatory cytokine pathway. Four members o f P38
MAPKs have been identified so far. They include p38, p38 beta, p38 gamma (Li et al.,
1996), and p38 delta (Jiang et al., 1997). MKK3 and MKK6 are upstream activators o f
P38 MAPK (Raingeaud et a l, 1996). Recently Enslen el a l, (1998) also reported that
the MAP kinase kinases MKK3 and MKK6 selectively activate p38 mitogen-activated
protein kinase isoforms, such as p38 alpha, p38 beta 2, and p38 gamma, suggesting the
MKK3 and MKK6 signaling pathways are coupled to separate, but overlapping groups
o f p38 MAPKs. P38 MAP kinases are weakly activated by mitogens, but strongly
activated by cell stresses, bacterial LPS, IL-1, and TNF-cc (Freshney et al., 1994; Lee et
a l, 1994; Rouse et a l, 1994; Raingeaud et al., 1995). Activated P38 MAP kinase in
turn phosphorylates cPLA2 (Kramer et al., 1995; Borsch-Haubold et al., 1997) and some
transcriptional factors including ATF2 (Raingeaud etal., 1995) and Elk-1 (Raingeaud et
al., 1996). It has been demonstrated that the pathways o f p38 MAPK and ERK are
cooperative for the activation o f NF-kB in TNF signaling pathway (Vanden Berghe et
al., 1998). Han et a l, (1997) also demonstrated that a possible link between the p38
MAPK pathway and a member of the myocyte-enhancer factor 2 (MEF2) group of
transcription factors, which are involved in inflammation. They indicated the increasing
transactivating activity of MEF2C by activated p38 MAPK in LPS signaling pathway.
These observations suggest that activated P38 MAPK and JNKs play a role in gene
expression.
I.2.3.3. JNKs/SAPKs
JNKs/S APKs are stress-responsive MAP kinases. These are activated by
ultraviolet (UV) irradiation and osmotic stress, and activated JNKs phosphorylate a
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transcription factor c-Jun (Derijard et al., 1994; Kyriakis et al., 1994; Pulverer et al.,
1991). MKK7 is an upstream activator of JNKs (Toumier et al., 1997; Foltz et al.,
1998). Activated JNK binds to the c-Jun transactivation domain and phosphorylates
both Ser-63 and Ser-73 in the c-Jun and activates the c-Jun (Hibi et al., 1993). Two
polypeptides (46 kDa and 54 kDa) exhibiting JNK activity have been identified by
biochemical characterization (Hibi et al., 1993). Although the module o f regulation is
similar, the 46 kDa polypeptide has a higher affinity for binding to c-Jun than the 54 kDa
polypeptide (Hibi et al., 1993). Under UV irradiation, both forms of JNK (JNK-46 and
JNK-54) are rapidly and potently activated (Devary et al., 1991; Hibi et al., 1993).
Similar to ERK-1 and ERK-2, JNK-1 requires dual phosphorylation at both Thr
and Tyr for activation. In structure, however, the dual phosphorylation site motif present
in JNK-1 (Thr-Pro-Tyr) is distinct from that located in ERKs (Thr-Glu-Tyr). These Thr
and Tyr residues are also conserved in JNK-1 and mutations of these residues inhibited
the phosphorylation and activation o f JNK-1 induced by UV treatment (Derijard et al.,
1994). The structure o f JNK-1 revealed homology to ERK-1 and ERK-2 (Boulton et al.,
1991) by comparison o f the deduced structure o f JNK-1 with ERK-1 and ERK-2 using
the GenBank data base (Blast Fileserver, National Center of Biotechnology Information)
(Boulton et al., 1990,1991). It has been observed that there is sequence homology
between JNK-1 and the yeast HOG1 MAP kinase (Brewster et al., 1993). JNK also
plays an important role in the activation o f the activating transcription factor 2 (ATF 2)
(Livingstone et al., 1995; van Dam et al., 1995; Botteron and Dobbelaere, 1998) and
another transcription factor, the activator protein-1 (AP-1) (Botteron and Dobbelaere,
1998), suggesting the involvement o f JNK on the gene expression.
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1.2.4. Src Protein Tyrosine Kinases
The Src family kinases, which are named after the src oncogene of Rous
sarcoma virus, are a type of non-receptor protein tyrosine kinases (PTKs) that play
important roles in eukaryotic signal transduction (Sicheri et al., 1997; Sicheri and
Kuriyan, 1997). So far, 9 Src family PTKs (Src, Lyn, Fgr, Hck, Fyn, Yes, Lck, Blk, and
Yrk) have been identified (Brown et al., 1996).
The Src family members share a common regulatory mechanism, but differ in
cellular expression and localization. The Src, Yes, Fyn, and Lyn are expressed in
various cell types, whereas the Lck, Hck, Fgr, and Blk are expressed primarily in
hemopoietic cells (Bolen et al., 1992). Hck is expressed primarily in lymphoid and
myeloid cells (Quintrell et al., 1987; Zeigler et al., 1988). Several members of the Src
family kinases are usually present in each cell type.
The Src family kinases are highly homologous in structure. The general
structure of the Src family kinases is shown in Figure 5. They all contain an N-terminal
myristylation domain, Src homology 2 (SH2) and Src homology 3 (SH3) domain, a
protein kinase domain (also designated as a catalytic domain), and a C-terminal
regulatory domain. The sequences necessary for fatty acylation (myristylation and
palmitylation) and stable membrane association are located at the amino terminus o f the
Src family kinases. Myristylation and palmitylation help the Src family kinases target to
the cell membranes. For example, a myristic acid is covalently bound to a common
glycine-2 by an amide linkage in most Src family kinases except Src kinase (Resh,
1990). Adjacent to this small domain is the 50- to 80- amino acids “unique” domain
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where the amino acid sequences between the Src family kinases diverge most
dramatically. The region of the Src family kinase extending from about 90- to 250amino acids represent sequences that share identity with other non-receptor protein
tyrosine kinases as well as other classes o f cellular regulatory and structural proteins.
This region can be subdivided into the roughly 50-amino acids SH3 domain and
approximately 100-amino acids SH2 domain (Bolen et a l, 1992). The majority of the
C-terminal half o f the Src kinases represents the catalytic domain, which is the region of
highest Src family sequence identity. Two important features in the catalytic domain
include the ATP binding site centered on a common lysine residue and the
autophosphorylation site on the tyrosine residue. The last 15- to 17-amino acids are
termed the C-terminal regulatory domain because deletion of these sequences or sitespecific mutation o f the tyrosine residue in the C-terminal regulatory domain to another
amino acid (e.g. phenylalanine) significantly activates the enzymatic function of Src
kinases. Such alterations render Src family kinases nonregulatable, and when expressed
in an appropriate cell type, these mutants are highly oncogenic (Bolen et a l, 1992).
Two major consensus tyrosine phosphorylation sites have been identified in Src
family kinases: (1) the autophosphorylation site on tyrosine residue in the catalytic
domain and (2) the phosphorylation site on tyrosine residue in the C-terminal regulatory
domain. Autophosphorylation on the tyrosine residue in the catalytic domain correlates
with the activation o f Src kinase activity, while phosphorylation on tyrosine residue in
the C-terminal regulatory domain suppresses its kinase activity (Cooper et a l, 1986).
As noted previously, the highly conserved regulatory apparatus o f the Src family
members consists of two peptide-binding modules, the Src homology domains SH2 and
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SH3. These modules bind to targets containing phosphotyrosines and polyproline type
II helices, respectively, and mediate the formation o f protein-protein complexes during
signaling (Pawson et al., 1995). It is likely that interaction between the SH2 domain
and a C-terminal phosphotyrosine residue in the Src kinases results in a decrease of
catalytic activity of Src kinases, with additional inhibitory interactions provided by the
SH3 domain.
The inhibitory phosphorylation at Tyr-527 in the C-terminal regulatory domain
o f c-Src is mediated by a distinct tyrosine kinase, c-Src kinase (Csk) (Nada et al., 1991).
It is now clear that phosphorylation of Tyr-527 by Csk inhibits Src catalytic activity by
creating an intramolecular binding site for the Src SH2 domain (Roussel et al., 1991).
In contrast, autophosphorylation at another tyrosine residue (Tyr-416 in c-Src), located
within the ‘activation segment’ o f the catalytic domain, is required for its catalytic
activity (Brown et al., 1996).
The catalytic domain of the Src kinases alone is functional as a tyrosine kinase,
but the Src SH2 and SH3 domains are required for full biological activity. Certain
mutations in these domains lead to host cell-dependent phenotypes, indicating that they
play a dual role in the Src kinases (Brown et al., 1996). Several lines o f evidence also
suggest that this regulation is governed by an intramolecular interaction between the
phosphorylated C-terminal tyrosine and the SH2 domain that somehow stabilizes the
inactive conformation of the kinases. The classically characterized v-src oncogene from
avian retroviruses encodes a constitutively active kinase (Takeya et al., 1983). Mutation
o f the conserved tyrosine (Tyr-527 in avian c-Src) to a phenylalalnine also creates an
active oncogenic protein (Hunter, 1987). It has been shown that COX is persistently
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induced in p60 v'src (Tyr-527 at the C-terminal regulatory domain in c-Src was replaced
with a phenylalanine)-transformed 3T3 fibroblasts (Han et al., 1990). It has been
reported that one o f the cDNAs induced in chicken embryo fibroblasts (CEFs) by
activation o f a temperature-sensitive w-src oncogene encodes a prostaglandin synthase
(PGS) (Simmons et al., 1991; Xie et al., 1991). p60 v'src induces prostaglandin
synthase-2 (PGS-2, COX-2) gene expression by activation of the c-jun N-terminal
kinase (JNK) and the c-jun transcription factor (Xie et al., 1995). Numerous studies
have shown that gene expression can be induced by p60 v‘src through different c/s-acting
regulatory elements, including AP-1 (Birchenall-Roberts et al., 1990), the serum
response element (SRE) (Qureshi et al., 1991), and a unique src-responsive element
(Dehbi et al., 1992). It has been demonstrated that the induction of TIS10/PGS2
prostaglandin synthase gene expression by v-Src is mediated by an ATF/CRE
transcription response element (Xie et al., 1994). These observations suggest a critical
role o f C-terminal tyrosine residue in regulating Src kinase activity and also imply that
many immediate early gene expressions including COX-2 gene can be induced by a
single amino acid change in another Src kinases.
While studying the structure and expression of \-yes, a clone, which is termed
Ick/yes-related novel tyrosine kinase (lyn), was isolated in human (Yamanashi et al.,
1987). This human lyn clone contains an open reading frame (ORF) which codes for a
mature Lyn protein with 512 amino acids (Rider et al., 1994). Subsequently the fulllength murine homologue of lyn was isolated (lyn A), as well as a smaller form (lyn B)
lacking 24-44 amino acids which was otherwise identical to the larger form (Yi et al.,
1991). Both forms o f lyn encoding p53 and p56 polypeptides are derived from a single
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gene by alternative splicing o f the RNA transcripts (Stanley et a l, 1991). Other
alternatively spliced RNAs in the Src family kinases, such as src and hck (gene
encoding hematopoietic cell kinase), are differentially expressed in various tissues or
subcellular fractions (Levy et a l, 1987; Lock et a l, 1991). However, the two isoforms
o f murine Lyn are coexpressed in all identified tissues and both bind the B-cell IgM
receptor (Stanley et a l, 1991).
Yamanashi et a l (1991) suggested that Lyn might be involved in the regulation
o f the immune response. Han et al. (1993) reported that initial interaction o f LPS with
monocytes and macrophages involves a LPS-binding protein (LBP) that binds to LPS
and a glycosylphosphatidylinositol-anchored cell surface glycoprotein, CD 14 receptor.
It has been shown that L ynp53/56 was co-immunoprecipitated with CD 14 in human
monocytes (Stefanova et al., 1993). These observations suggest a functional role of Lyn
kinase as the immediate upstream activator in the LPS/CD14-mediated signal
transduction pathways in monocytes and macrophages that lead to COX-2 expression.
1.2.5. Nuclear Factor-kappa B (NF-kB)
It has been reported that NF-kB induces the expression of many effector proteins
involved in immune response, inflammation, and the transcription of numerous genes
encoding cytokines, or growth factors (Siebenlist et a l, 1994). The transcriptional
regulation o f adhesion molecules, enzymes, and cytokines involved in chronic
inflammatory diseases is controlled by the transcription factor NF-kB (Barnes et a l,
1997).
The active NF-kB that binds to DNA in dimeric complexes is composed of
various combinations o f members o f the Rel/NF-kB family (Siebenlist et a l, 1994).
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The Rel/NF-kB family is distinguished by the presence of a so-called Rel homology
domain (RHD) o f about 300 amino acids in length, which shows 35-61% identity
between this family members (Bours et al., 1992; Ryseck et al., 1992). The RHD
determines DNA binding to kB elements, dimerization with identical or other members
o f the family, as well as interaction with the IkB family of proteins (Siebenlist et a l,
1994).
The Rel/NF-kB family members can be divided into two classes. One is the
pl05 and plOO precursor proteins, which are processed proteolytically to the mature p50
and p52 forms, respectively (Ghosh et a l, 1990; Schmid et a l, 1991). The other class is
the Rel (c-Rel), v-Rel, RelA (p65), and RelB proteins (Stephens et al., 1983; Nolan et
a l, 1991; Ruben et a l, 1991; Ryseck et a l, 1992). The members of the Rel/NF-kB
family of proteins can form almost all theoretically possible homo- and heterodimes,
making many complexes through combinatorial mixing (Siebenlist et al., 1994).
Dimerization is necessary for DNA binding (Bressler et a l, 1993). Thep50/RelA
(p50/p65) complex is usually the most abundant dimeric complex and is present in
essentially most type of cells. Among the other possible dimeric complexes,
homodimers o f RelA or Rel or RelA/Rel heterodimers are only formed at very low
levels. Such complexes may, nevertheless, play unique and critical roles on specific
promoters (Hansen et al., 1992; Nakayama et al., 1992; Ganchi et a l, 1993; Kunsch and
Rosen, 1993). The various dimeric complexes have a different preference for certain kB
sites, transactivation potentials, kinetics o f nuclear translocation, and levels o f
expression in tissues (Siebenlist et al., 1994). In response to extracellular activation, the
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nearly ubiquitously expressed p50/RelA is likely to be rapidly translocated to the
nucleus (Molitor et al., 1990), where gene transcription occurs.
The highly conserved RHD, which is also the only region shared by all members
of this family, plays a significant role for DNA binding, dimerization, nuclear
translocation, and binding to IkB inhibitors (Siebenlist et al., 1994). A short stretch o f
amino acid domain (the so-called RXXRXRXXC motif) in RHD contacts DNA directly
(Kumar et al., 1992, 1993). Since its oxidation interferes with DNA binding, the
cysteine residue within this motif should be in a reduced state (Toledano and Leonard,
1991; Kumar etal., 1992; Mattews etal., 1992; Hayashi etal., 1993). A second region
about 100 amino acids further C-terminal to the RHD is significant because of possible
DNA binding (Bressler et al., 1993). The C-terminal end of the RHD possesses
conserved and positively charged amino acids, which function as a nuclear localization
sequence (NLS) and possibly interact with the inhibitory IkB proteins (Blank et al.,
1991; Beg et al., 1992; Henkel et al., 1992).
Different NF-kB dimers have different binding affinities to certain kB sites
(Urban and Baeuerle, 1990; Bours et al., 1992b; Perkins et al., 1992; Franzoso et al.,
1993). Most kB elements are somewhat palindromic, which gives these elements a
directional sense relative to the transcriptional start site (Urban and Baeuerle, 1990,
1991).
The IkB family of proteins includes DcB-a, EkB-P, the precursor protein p i 05
and plOO, IkB-y, and Bcl-3. IkB-a and IkB-P have a difference in molecular weights
(IkB-cc is 37 kDa and IkB-p is 43 kDa) (Zabel and Baeuerle, 1990). Based on lack of
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immunological cross-reactivity, and a difference in molecular weights, it is suggested
that IkB-p may be encoded by a separate gene from IkB-a (Siebenlist et al., 1994).
All members o f the IkB family have a partially conserved domain that contains
six to eight ankyrin motifs, each 33 amino acids in length (Schmitz et al., 1991; Blank
et al., 1992; Nolan and Baltimore, 1992). It has been believed that the ankyrin motifs in
this IkB family regulate NF-kB activity (Kieran et al., 1990) by inhibiting nuclear
translocation and DNA binding of Rel/NF-kB complexes. Among the IkB family, IkBa interacts with and shields the nuclear localization signal (NLS) located at the Cterminal end of the RHD domain of NF-kB (Beg et al., 1992; Ganchi et al., 1992;
Henkel et al., 1992). Hatada et al. (1992,1993) reported that IkB-a shields the
positively charged NLSs of both subunits of all dimeric NF-kB complexes, suggesting
that a short, negatively charged region of IkB-a located adjacent to the most C-terminal
(sixth) ankyrin motif may be critical.
Activation of NF-kB from cytoplasmic pools correlates with proteolytic
degradation o f the inhibitory IkB-a protein. An observation that has been confirmed in
many laboratories is that almost complete degradation o f IkB-a protein occurs within
minutes following stimulation with extracellular stimuli including TNF-a or PMA (Beg
etal., 1993; Brown etal., 1993; Sunef al., 1993; Henkel etal., 1993; Read etal., 1994).
In addition, a post-translational phosphorylation o f IkB-a is required for the degradation
oflkB -a (Beg etal., 1993; Brown etal., 1993; Cordle eta l., 1993; Sun etal., 1993).
The phosphorylated form o f IkB-a is transiently and shortly detected as a protein
showing slightly retarded electrophoretic mobility after stimulation o f cells. As IkB-a
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degradation occurs, NF-kB becomes active and translocates to the nucleus to induce
specific gene transcription (Brown et al., 1993; Sun et al., 1993). The molecular
mechanisms of NF-kB activation by the degradation o f IkB-a are displayed in Figure 6.
Free and uncomplexed IkB-a is unstable in cells, whereas complexed IkB-a is
stable in cells. It has been indicated that the phosphorylation of IkB-a releases the
inhibitor from NF-kB, thereby leaving it unprotected from active proteases, which then
degrade the free form o f IkB-a (Beg et al., 1993; Brown et al., 1993; Sun et al., 1993).
This observation is based on early reports indicating that several kinases activate IkB-abound NF-kB in vitro and phosphorylate and inactivate partially purified IkB-a
(Shirakawa and Mizel, 1989; Ghosh and Baltimore, 1990).
The kinase(s) directly responsible for mediating signal-dependent
phosphorylation o f IkB-a have been reported. Li and Sedivy (1993) reported that IkB-a
could be phosphorylated by Raf in vitro. Constitutively active NF-kB is detected in
cells transfected with active forms of Raf. However, cells that overexpress dominant
negative forms of R af did not contain active NF-kB upon exposure to TNF-a, serum,
PMA, or UV irradiation ( Devary et al., 1993; Finco and Baldwin, 1993; Li and Sedivy,
1993). Raf may act as an IkB-a kinase (IKK) through a direct physical interaction
between Raf and IkB-a by using a yeast two-hybrid analysis in which genes for both
proteins were introduced in cells (Li and Sedivy, 1993). Consistent with a role o f NFkB in a defensive response, the pro-inflammatory cytokines such as TNF-a, TNF-P, and
IL-1 are potent activators o f NF-kB in most type o f cells (Osbom et al., 1989; Messer et
al., 1990). For example, TNF-a-induced activation of NF-kB is blocked by
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Figure 6. The molecular mechanism o f NF-kB activation (Bames and Karin, 1997).

34

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

overexpression of dominant negative Raf mutant (Devary et al., 1993; Finco and
Baldwin, 1993). Since MAPKs, a downstream effector of Raf, are activated by TNF
treatment (Saklatvala et al., 1993), Raf may lie on this pathway, supporting the previous
hypothesis that Raf may be a possible kinase that phosphorylates IkB-a. Other studies
suggest an essential role for protein kinase C (PKC) zeta in TNF-a signaling pathway
which leads to activation of NF-kB. This view is based on that active NF-kB is detected
by overexpression of constitutively active PKC zeta protein in NIH/3T3 cells (DiazMeco et al., 1993).
Reactive oxygen intermediates (ROIs) play a role as a common and critical
messenger molecule for various activating signals (Schreck et al., 1992a, 1992b). This
observation is based on that a variety of antioxidants block NF-kB activation. For
example, pyrolidinedithiocarbamate (PDTC), an antioxidant, blocks the degradation of
IkB-a induced by the treatment with TNF-a and PMA in some Jurkat T cell lines (Beg
et al., 1993; Henkel et al., 1993; Sun et al., 1993). Evidence showing elevated cellular
levels o f ROIs in response to TNF-a, IL-1, PMA, LPS, UV light, and gamma-irradiation
supports the possible involvement o f ROIs as common messenger molecules (Schreck et
al., 1992a,1992b; Geng etal., 1993, Schieven et a l, 1993). Among ROIs such as
hydrogen peroxide, hydroxyl radicals, superoxide, and singlet oxygen, only hydrogen
peroxide treatment results in activation of NF-kB in cells (Schreck et al., 1991,1992a),
suggesting that peroxides may play a critical role in the NF-kB signaling cascades. It
also has been shown that the inhibitors of PTKs block NF-kB activation following
gamma-irradiation, a stimulant that is believed to act primarily through the immediate
generation o f ROIs (Schieven et al., 1993). It is suggested that PTKs might function
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prior to the generation o f ROIs (Siebenlist et al., 1994). Despite these observations, a
direct role of ROIs in NF-kB activating signaling mechanisms has not been
demonstrated.
Mitogenic stimuli are believed to activate NF-kB. Baldwin et al. (1991)
demonstrated that activation of NF-kB was transiently induced by serum stimulation in
fibroblast cultures that were grown in the absence o f serum. The active NF-kB was
detected in Human immunodeficiency virus (HlV)-infected monocytic cells (Bachelerie
et al., 1991; Paya et al., 1992). The treatment of okadaic acid and calyculin A,
inhibitors of phosphatases 1A and 2A, results in NF-kB activation (Thevenin et al.,
1990; Menon et al., 1993, 1995), suggesting the possible involvement of a negatively
acting phosphatase in the signal transduction to IkB-a.
High levels of endogenous IkB-a mRNA were detected in cells transfected with
transactivating NF-kB subunits (Brown etal., 1993; Scott etal., 1993; Sun etal., 1993;
Read et al., 1994). It has been verified that the IkB-a promoter possesses kB binding
sites, depending on transcription of IkB-a gene by NF-kB (de Martin et al., 1993; Chiao
et al., 1994). The expression o f IkB-a, which presumably is destined to restore the
inhibited state, is regulated by transactivating NF-kB dimers (Brown etal., 1993).
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CHAPTER 2
MATERIALS AND METHODS
2.1. Reagents
Preparations o f LPS from E.coli 0111 :B4 strain were purchased from Difco
Laboratories Co. (Grand Island, NY). Mouse monoclonal anti-phosphotyrosine
antibody (4G10) was purchased from Upstate Biotechnology, Inc. (UBI, Lake Placid,
NY). Rabbit polyclonal anti-ERK-2, anti-JNK-1, and anti-P38 antibodies were
purchased from Santa Cruz Biotech. (Santa Cruz, CA). Rabbit polyclonal anti-P38
antibody was a gift from Dr. R. J. Ulevitch (The Scripps Research Institute, La Jolla,
CA). Myelin Basic Protein (MBP) was purchased from GIBCO-BRL (Grand Island,
NY). Rabbit muscle enolase was purchased from Sigma (St. Louis, MO). E.coli
bacteria containing GST-ATF2 fusion protein was obtained from Dr. R. J. Davis
(Program in Molecular Medicine and Howard Hughes Medical Institutes, University of
Massachusetts Medical School, Worcester, MA). Goat anti-mouse and anti-rabbit
immunoglobulin G (IgG) antibodies conjugated to horseradish peroxidase were
purchased from Amersham Corp. (Arlington Heights, IL). Enhanced
chemiluminescence (ECL) western blotting detection reagent and [y-32P] adenosine 5’triphosphate (ATP) were purchased from Amersham Corp. Polyvinylidene difluoride
(PVDF) transfer membrane was purchased from Millipore (Bedford, MA). Arachidonic
acid was purchased from Nu-Chek (Eslyan, MN). Radicicol (an inhibitor o f p60src) was
provided by Dr. H. J. Kwon and Dr. T. Beppu (Dept, o f Biotechnology, Tokyo Univ.,
Japan). Z-LLF-CHO (an inhibitor o f BcBa degradation) was provided by Dr. F.
Mercurio (Signal Pharmaceuticals). PD98059 (an inhibitor o f MEK-1 and MEK-2) was
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obtained from Dr. A. Saltiel (Parke-Davis Pharmaceuticals). SB203580 (an inhibitor of
P38) was obtained from Dr. P. Young (SmithKline Beecham Pharmaceuticals). An
RPAII™ kit used for ribonuclease protection assay was purchased from Ambion Inc.
(Austin, Texas). Sequenase™ Quick-Denature™ Plasmid Sequencing Kit was
purchased from United States Biochemical (USB, Cleveland, OH). Phoenix (<DNX)amphotropic cells (a ONX helper-free retrovirus producer line) were provided by Dr. G.
P. Nolan (Dept, of Molecular Pharmacology and Microbiology and Immunology,
Stanford University School o f Medicine, Stanford, CA). pBPSTRl retroviral vector
was provided by Dr. S. A. Reeves (Molecular Neuro-Oncology Laboratory,
Massachusetts General Hospital-East, Charlestown, MA). Human lyn cDNAs were
subcloned in pBPSTRl retroviral vector with modification by Dr. M. Awad, a previous
post-doctorate in the laboratory of Dr. D. Hwang (Lab. of Prostaglandin Metabolism,
Pennington Biomedical Research Center, LSU, Baton Rouge, LA).
2.2. Cell Culture
RAW 264.7 cells (an Abelson virus-transformed murine macrophage cell line,
ATCC TIB-71) were maintained in Dulbecco’s modified Eagle’s medium (DMEM,
GIBCO-BRL) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS,
Intergen) and 1% (v/v) antibiotics (penicillin/streptomycin, Sigma) at 37° C in 5%
CCVair mixtures. Before stimulation, 5 x 106or 10 x 106 of RAW 264.7 cells were
plated into a 60-mm or 100-mm dish (Coming) in 5 ml or 10 ml of DMEM
containinglO% (v/v) heat-inactivated fetal bovine serum (FBS) and 1% (v/v) antibiotics
(penicillin/streptomycin). Cells were then grown for 18 hours to allow the number of
cells to approximately double. After 18 hours, the culture media was removed and cells
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were washed with DMEM containing 1% antibiotics (Penicillin/Streptomycin). After
washing, cells were pretreated or treated with the appropriate agents for different time
periods.
To examine whether the activation of MAPKs alone is sufficient to induce the
expression o f COX-2, known activators of MAPKs, such as PMA, sorbitol, H2 O2 , or
combinations of these factors (PMA plus sorbitol or PMA plus H 2 O2 ) were used. For
the activation of MAPKs, RAW 264.7 cells were treated with LPS (1 pg/ml), PMA (100
nM), sorbitol (0.4 M), H2 O2 (1 mM),or PMA (100 nM) plus sorbitol (0.4 M) and PMA
(100 nM) plus H2 O2 (1 mM) for 30 minutes. For the expression o f COX-2 mRNA and
protein, RAW 264.7 cells were treated with LPS (1 pg/ml), PMA (100 nM), sorbitol
(0.4 M), H2O 2 (1 mM),or PMA (100 nM) plus sorbitol (0.4 M) and PMA (100 nM) plus
H2 O2 (1 mM) for 4 hours and 8 hours, respectively.
To examine whether inhibition of LPS-induced activation o f MAPKs
(particularly ERK-1, ERK-2, or P38 MAP kinase) is involved in the regulation of COX2 expression, the inhibitors o f MAPKs, PD98059 and SB203580, were used. First, for
the inhibition o f ERK-1 and ERK-2, RAW 264.7 cells were pretreated with PD98059 in
different concentrations (0,1,10, 50, 100, and 200 pM) for 1 hour in the absence of
LPS. After pretreatment, RAW 264.7 cells were washed with DMEM containing 1%
antibiotics (Penicillin/Streptomycin) three times. After washing, RAW 264.7 cells were
treated with LPS (1 pg/ml) plus PD98059 in the same concentrations used in
pretreatment for 30 minutes. The effect of PD98059 treatment on the regulation o f
COX-2 protein activity was examined by radioimmunoasay to measure the amount of
PGE2 generated by COX-2. The amount o f PGE2 was used as an indication o f COX-2
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protein activity. For the measurement o f COX-2 activity, 0.5 x 106 cells per well were
plated in 24-well plates and grown for 18 hours to double the number o f cells. After 18
hours, RAW 264.7 cells were treated with LPS (1 pg/ml) plus PD98059 in the same
concentrations previously used for the inhibition of ERK-1 and ERK-2 for 8 hours.
After 8 hours, the culture media was removed and arachidonic acid (30 pM) as an
exogenous substrate o f COX-2 was added to cells for 10 minutes. The conditioned
culture media was removed and analyzed by radioimmunoassay to measure the amount
of prostaglandin E2 (PGE2 ) produced by COX-2. Second, to examine whether
inhibition o f LPS-induced activation of P38 MAP kinase is also involved in the
regulation o f COX-2 expression, RAW 264.7 cells were pretreated with SB203580 at
different concentrations (0,0.05,0.25, 1.25, 6.25,12.5, and 37.5 pM) for 1 hour in the
absence o f LPS. After pretreatment, RAW 264.7 cells were washed with DMEM
containing 1% antibiotics (penicillin/streptomycin) three times. After washing, RAW
264.7 cells were treated with LPS (I pg/ml) plus SB203580 in the same concentrations
used in pretreatment for 30 minutes. For the inhibition o f COX-2 expression, RAW
264.7 cells were treated with LPS (1 pg/ml) plus SB203580 in the same concentrations
previously used for the inhibition o f P38 MAP kinase for 8 hours without pretreatment.
For the time course o f LPS-induced NF-kB activation, RAW 264.7 cells were
treated without or with LPS (1 pg/ml) for different time periods (0, 1, 5, 10,20,30,60,
and 120 minutes). Since it has been shown that NF-kB activation following the
treatment o f agonists correlates with rapid proteolytic degradation o f IkB-a protein
induced by agonists, LPS-induced degradation o f IkB-a protein was used as an
indication o f NF-kB activation. To examine whether inhibition o f LPS-induced

40

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

activation of NF-kB is involved in the regulation of COX-2 expression, an NF-kB
inhibitor, Z-LLF-CHO, was used and inhibition of IkB-a degradation was examined as
an indication of NF-kB activity. For the inhibition of IkB-a degradation, RAW 264.7
cells were pretreated with Z-LLF-CHO at different concentrations (0, 1, 5, and 10 pM)
for 1 hour in the absence o f LPS. After pretreatment, RAW 264.7 cells were washed
with DMEM containing 1% antibiotics (penicillin/streptomycin) three times. Following
a wash, RAW 264.7 cells were treated with LPS (1 pg/ml) plus Z-LLF-CHO in the
same concentrations used in pretreatment for 30 minutes. For the inhibition o f COX-2
expression, RAW 264.7 cells were treated with LPS (1 pg/ml) plus Z-LLF-CHO in the
same concentrations previously used for the inhibition of IkB-a degradation for 8 hours
without pretreatment.
To examine whether both inhibition of LPS-induced activation of MAPKs and
NF-kB is involved in the regulation of COX-2 expression, the inhibitors of protein
tyrosine kinases (PTKs), such as Radicicol and Herbimycin A, were applied. For the
inhibition of MAPKs, RAW 264.7 cells were pretreated with Radicicol in different
concentrations (0,0.001,0.01,0.1, and 1 pg/ml) or Herbimycin A at the concentration
o f 0.5 pg/ml for 3 hours in the absence o f LPS. After pretreatment, RAW 264.7 cells
were washed with DMEM containing 1% antibiotics (penicillin/streptomycin) three
times. Following a wash, RAW 264.7 cells were treated with LPS (1 pg/ml) plus
Radicicol or Herbimycin A for 30 minutes. For the inhibition o f COX-2 expression,
RAW 264.7 cells were treated with LPS (1 pg/ml) plus Radicicol or Herbimycin A for 8
hours without pretreatment.
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2.3. Sample Preparation
For anti-phosphotyrosine immunoblotting analysis (see section 2.4.), RAW
264.7 cells treated with known activators and/or inhibitors of MAPKs for 30 minutes
were washed with ice-cold phosphate buffered saline (PBS) containing 1 mM sodium
vanadate (Na3 V 0 4 ), which is an inhibitor o f protein tyrosine phosphatases (PTPs).
Following a wash, cells were lysed in buffer [50 mM Tris-HCl (pH 7.4), 10 mM EDTA,
1% (v/v) Tween-20,1% (v/v) Triton X -100,10 pM leupeptin, 1 mM
phenylmethylsulfonyl fluoride (PMSF), 1 mM sodium vanadate (Na3 V0 4 )] and set on
ice for 20 minutes. Cell lysates were collected on ice and centrifuged at 14,000 rpm
(10,000 x g) for 20 minutes at 4° C. After centrifugation, the supernatant was
transferred to a 1.5-ml tube and the protein concentrations were measured by the
Bradford method. Solubilized proteins were used for anti-phosphotyrosine
immunoblotting analysis. The same cell lysates used for anti-phosphotyrosine
immunoblotting analysis were also used for western blotting analysis (see section 2.5.)
for the detection of JNK-1, IkB-a or immunoprecipitation (see section 2.6.) for the
detection of ERK-2, P38 MAP kinase.
For ribonuclease protection assay (see section 2.11.), RAW 264.7 cells were
treated with known activators o f MAPKs for 4 hours and washed with ice-cold PBS
without sodium vanadate. After washing, cells were lysed in TRIZOL reagent
(Quiagen) (3 ml/60-mm size plate) by passing the cell lysates several times through a
pipette. The homogenized samples were incubated for 5 minutes at room temperature to
permit the complete dissociation o f nucleoprotein complexes and then mixed with
chloroform (0.2 ml/1 ml TRIZOL reagent). Following vigorous shaking, the samples
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were incubated at room temperature for 3 minutes and centrifuged 12,000 x g for 15
minutes at 4° C. After centrifugation, only the aqueous phase containing RNA was
transferred to a 1.5-ml tube and the RNA from the aqueous phase was precipitated by
mixing with isopropanol (0.5 ml/1 ml TRIZOL reagent). Following incubation for 10
minutes at room temperature, the samples were centrifuged at 12,000 x g for 15 minutes
at 4° C. After removing the supernatant, the RNA pellet was washed with 75% ethanol
(1 ml/1 ml TRIZOL reagent) and centrifuged at 7,500 x g for 5 minutes at 4° C. The
washed RNA pellet was briefly dried for 5-10 minutes at RT. The dried RNA pellet
was dissolved in TE buffer (Tris-Cl, EDTA, pH 8.0) and the concentration of RNA was
measured at OD260 /2 80 For COX-2 and GAPDH western blotting analysis (see section 2.5.), RAW
264.7 cells were treated with activators and/or inhibitors for 8 hours and washed with
ice-cold PBS in the absence o f sodium vanadate. Following a wash, cells were
harvested in lysis buffer [50 mM Tris-HCl (pH 7.4), 1 mM sodiumdiethyldithiocarbamic acid (Na-DDTC), 10 mM EDTA, 1% (v/v) Tween-20,1% (v/v)
Triton X-100, 10 pMleupeptin, 1 mM phenylmethylsulfonyl fluoride (PMSF)] for 20
minutes on ice. Cell lysates were sonicated (35 strokes) on ice and centrifuged at
14,000 rpm (10,000 x g) for 30 minutes at 4° C. After centrifugation, the supernatant
was saved and the protein concentrations were measured by the Bradford method.
Solubilized proteins were used for COX-2 and GAPDH western blotting analysis.
2.4. Anti-Phosphotyrosine Immunoblot Analysis
The purpose o f anti-phosphotyrosine immunoblotting analysis is to examine
proteins that are tyrosine phosphorylated in RAW 264.7 cells following stimulation.

43

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

For this assay, mouse monoclonal anti-phosphotyrosine antibody (also designated as
4G10) was used because it specifically recognizes proteins containing phosphorylated
tyrosine residues. Solubilized proteins (80 pg) prepared previously (see section 2.3.)
were separated on a 12% sodium dodecyl sulfate (SDS) polyacrylamide gel. Following
electrophoresis, separated proteins on gel were transferred to a polyvinylidene difluoride
(PVDF) transfer membrane (Millipore) in cold transfer buffer (10 mM Na 2 CC>3 , 3 mM
NaHC 0 3 , 20 % v/v methanol, pH 9.9). The membrane was then blocked in Trisbuffered saline-0.1% (v/v) Tween 20 (TBST) containing 3% (w/v) bovine serum
albumin (BSA, Sigma) for 2 hours at room temperature or overnight at 4° C with slow
shaking. After blocking, the membrane was washed in TBST at room temperature and
then incubated in TBST containing mouse monoclonal anti-phosphotyrosine antibody
(4G10) (1:2,000 dilution) for 1 hour at room temperature or overnight at 4° C with slow
shaking. The membrane was washed in TBST and then incubated in TBST containing
goat anti-mouse IgG coupled to horseradish peroxidase (1:5,000 dilution) at room
temperature for 1 hour. Finally, the membrane was washed in TBST and then treated
with enzyme chemiluminescence (ECL) western blotting detection reagent (Amersham)
for 1 minute at room temperature. The membrane was briefly dried and exposed on an
ECL western detection film (Amersham) at room temperature in the dark room. The
exposed film was developed. After anti-phosphotyrosine immunoblotting analysis, the
membrane was stripped in stripping buffer and reprobed with appropriate antibodies to
locate the tyrosine phosphorylated proteins. Briefly, the same membrane used for antiphosphotyrosine immunoblotting was stripped in stripping buffer [50 mM Tris-HCl,
100 mM p-mercaptoethanol, 2% (w/v) SDS, pH 6.5] at 50° C for 1 hour with slow
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shaking in order to remove antibodies attached on the membrane. Following a wash,
the stripped membrane was reprobed with appropriate antibodies such as anti-ERK-1,
anti-ERK-2, anti-P38, anti-JNK-1, anti-IkB-a, or anti-Lyn antibodies.
2.5. Western Blot Analysis
The purpose o f western blotting analysis is to quantitatively compare the total
amount of protein following treatment. The basic procedure of this analysis was similar
to that of anti-phosphotyrosine immunoblotting analysis (see section 2.4), described
previously. Briefly, 80 pg of solubilized proteins were separated on 8% SDSpolyacrylamide gel for JNK-1, COX-2, and GAPDH western blotting analysis or 12%
SDS-polyacrylamide gel for IkB-a western blotting analysis. Following electrophoresis,
separated proteins on the gel were transferred to a PVDF transfer membrane with the
same conditions described previously (see section 2.4.). However, the membrane was
blocked in Phosphate buffered-saline (PBS)-0.l% (v/v) Tween 20 (PBST) containing
5% (w/v) non-fat dried milk (Carnation, San Francisco, CA) with slow shaking
overnight at 4° C. After blocking, the membrane was washed in PBST and then
incubated in PBST containing appropriate antibodies for 1 hour at room temperature.
These antibodies included rabbit polyclonal anti-P38 (1:10,000 dilution), anti-ERK-2
(1:10,000 dilution), anti-Lyn (1:2,000 dilution), anti-c-Src (1:1,000 dilution), anti-Flag
(1:2,000), anti-JNK-1 (1:2,000 dilution), anti-IkB-a (1:1,000 dilution), anti-COX-2
(1:10,000 dilution), or anti-GAPDH (1:10,000 dilution) antibodies. Following
incubation with primary antibodies, the membrane was washed in PBST and then
incubated in PBST containing sheep anti-rabbit IgG coupled to horseradish peroxidase
(1:5,000 dilution) as a secondary antibody for 1 hour at room temperature with slow
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shaking. Finally, the membrane was washed in PBST and treated with ECL western
blot detection reagent for 1 minute at room temperature. The membrane was exposed to
an ECL western film and the exposed film was developed.
2.6. Immunoprecipitation
The purpose o f immunoprecipitation is to qualitatively identify and purify each
protein of interest by immunoprecipitating it with its specific antibody. The proteins
immunoprecipitated in this study include ERK-2, P38, JNK-1, Lyn, Flag-tagged Lyn,
and COX-2 proteins. To identify and purify ERK-2, P38, JNK-1, or COX-2 proteins
affected by LPS or other agents, cell lysates were prepared from RAW 264.7 cells
unstimulated and stimulated with LPS or other agents and the ceil lysates were
immunoprecipitated with their specific antibodies. Following immunoprecipitation, the
immunoprecipitates were analyzed by western blot analysis using anti-ERK-2, anti-P38,
anti-JNK-1, or anti-COX-2 antibodies. To determine tyrosine-phosphorylated ERK-2 or
P38, cell lysates from LPS-stimulated RAW 264.7 cells were first immunoprecipitated
with anti-ERK2 antibody or anti-P38 antibody and the immunoprecipitates containing
ERK-2 or P38 were analyzed by anti-phosphotyrosine immunoblotting with an antiphosphotyrosine antibody (4G10). The best conditions of the ratio between the amount
of samples and the amount o f antibody for immunoprecipitation were different for each
protein. For example, about 100 pg of solubilized proteins and 2 pg o f anti-ERK-2
antibody were needed to show better immunoprecipitation results for ERK-2 analysis.
For Lyn analysis, about 500 pg of solubilized proteins and 5 pg of anti-Lyn antibody
were needed for immunoprecipitation. For JNK-1, about 200 pg of solubilized proteins
and 0.2 pg o f anti-JNK-1 antibody were used for IMP o f JNK-1. Following
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immunoprecipitation, the immunocomplexes containing each antigen and antibody were
further incubated in PBS containing protein A-sepharose beads for 3 hours at 4° C and
then centrifuged at 14,000 rpm (10,000 x g) at 4° C for 5 minutes. The supernatant
(SUP) was saved and concentrated with Centricon-10 (Amicon) by centrifugation at
6,000 rpm at 4° C to be about 80 pi o f a final volume. The pellets containing a complex
of antigen-antibody-protein A-sepharose beads were washed in ice-cold PBS. Each
washing step was followed by centrifugation at 14,000 rpm (10,000 x g) at 4° C for 3
minutes. After the final centrifugation, any residual solution in the upper phase was
completely removed by repeated pipetting. The pellets were then resuspended in 80 pi
of 2 x Laemmli buffer and boiled at 100° C for 5 minutes. The boiled pellets were
centrifuged at 14,000 rpm (10,000 x g) at 4°C for 5 minutes. After centrifugation, the
upper phase was saved. Both fraction of the immunoprecipitation were loaded on a
10% SDS-polyacrylamide gel for western blot analysis or a 12% SDS-polyacrylamide
gel for anti-phosphotyrosine immunoblotting analysis.
2.7. Radioimmunoassay
The purpose o f radioimmunoassay is to measure the amount o f prostaglandin E2
(PGE2 ) produced by COX-2 following treatment. The assay was performed according
to the method previously described (Fu et al., 1990) with modification. RAW 264.7
cells were incubated in DMEM containing 10% FBS with LPS or other agents for 8
hours. The culture media was removed, and the cells were incubated in the fresh
DMEM containing arachidonic acid (30 pM) as COX-2 substrate for 10 minutes. The
conditioned culture media was removed and analyzed to measure the amount o f PGE2
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produced by COX-2. The amount of PGE2 was used as an indication of COX-2 protein
activity.
2.8. In-Gel Kinase Assay for ERK-1, ERK-2, and JNK-1
To determine the kinase activity o f MAPKs following stimulation, an in-gel
protein kinase assay was performed using exogenous substrates with [y-32P] ATP. Two
exogenous substrates were used in the assay: myelin basic protein (MBP) as an ERK-1
& ERK-2 substrate and the activating transcription factor 2 (ATF2) as a JNK-1 substrate
(Derijard et al., 1995). The assay was performed according to the method previously
described (Kameshita, I., and Fujisawa, H., 1989; Gotoh et al., 1990; CamposGonzalez, R., and Glenney, Jr., J. R., 1992) with modification. The same samples from
RAW 264.7 cells treated with LPS plus the inhibitors [PD98059 (the inhibitor of MEK1 and MEK-2) or Radicicol and Herbimycin A (the inhibitors of protein tyrosine
kinases)] for anti-phosphotyrosine immunoblotting analysis (see section 2.4) were used
for this assay. For the measurement of ERK-1 and ERK-2 kinase activity, 100 pg of
solubilized proteins were resolved on a 10% SDS-polyacrylamide gel containing 5 mg
o f MBP as an ERK-1 and ERK-2 substrate. For the measurement of JNK-1 kinase
activity, the same procedures used for measuring ERK-1 and ERK-2 kinase activity
were followed except the use o f 5 mg o f purified glutathione-S-transferase (GST)-ATF2
(see section 2.8.1.) as a JNK-1 substrate instead o f MBP. These substrates were added
in the separation gel just prior to polymerization and evenly distributed in the separation
gel. After electrophoresis, SDS in the gel was removed by washing the gel twice with
each 200 ml o f SDS removal buffer [20% p-isopropanol in 50 mM Tris-HCl (pH 8.0)]
for 1 hour at RT with gentle agitation, and once more with 250 ml of 50 mM Tris-HCl
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(pH 8.0) containing 5 mM P-mercaptoethanol (Buffer A). To denature proteins in the
gel, the gel was treated with two changes of 200 ml of Buffer A containing 6 M
guanidine-HCl at RT for 30 minutes. To renature proteins in the gel, the gel was treated
with five changes o f 250 ml o f Buffer A containing 0.04% Tween 40 (pH 8.0) at 4° C
for 16 hours with gentle agitation. After renaturation, the gel was preincubated in 40
mM HEPES-NaOH (pH 8.0) containing 2 mM dithiothreitol (DTT), 0.1 mM EGTA,
and 5 mM MgCl2 at 25° C for 30 minutes. The kinase reaction was carried out by
incubating the gel in 40 mM HEPES-NaOH (pH 8.0) containing 2 mM dithiothreitol
(DTT), 0.1 mM EGTA, 5 mM MgCl2, 50 pM ATP, and 50 pCi of [y-32 P] ATP
(3,000Ci/mmol, 5 pCi/pl) at 25° C for 1 hour. After the kinase reaction, the gel was
washed with 5% (w/v) trichloroacetic acid (TCA) solution containing 1% sodium
pyrophosphate at RT until the radioactivity of the solution became negligible. The gel
was then dried on Whatmann 3MM filter paper in gel dryer at 80° C for 1 hour. The
dried gel was exposed to Kodak X-ray film. The kinase activity of ERK-1 & ERK-2 or
JNK-1 was assessed by the extent of incorporated y-32P in MBP by ERK-1 & ERK-2 or
ATF2 by JNK-1.
2.8.1. Purification of GST-ATF2 Fusion Protein
ATF2 is a known JNK-1 substrate (Fuchs et al., 1997). pGEX-3T/ATF2
plasmid DNA encoding GST-ATF2 fusion proteins (provided by Dr. R. J. Davis) was
transformed in E. coli DH-5a (GIBCO-BRL) by electroporation. To purify GST-ATF2
fusion protein from transformed E.coli bacteria harboring the pGEX-3T/ATF2 plasmid
DNA, glutathione sepharose 4B-column (Pharmacia Biotech.) was applied, and the
column purification procedure was performed according to the manufacturer’s
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instruction. Briefly, following electroporation, a single colony o f transformed E. coli
DH-5a was inoculated in LB (Luria Bertani) media containing 100 pg/ml of ampicillin
because o f the presence o f ampicillin-resistant genes in the pGEX-3T/ATF2 plasmid)
and further grown with vigorous shaking (250 rpm) overnight at 37° C. The cell culture
was then diluted to 1:10 in new LB media containing 100 pg/ml of ampicillin and
allowed to grow at 37° C for 1-3 hours with vigorous shaking. Bacterial growth was
induced with isopropyl-p-thio-galactopyranoside (IPTG) to a final concentration of 0.1
mM as a growth inducer and continued to grow at 37° C for an additional 3 hours.
When the ODeoo value reached 1.5-2.0, the culture suspension was transferred to clean
tubes and centrifuged at 8,000 rpm (7,700 x g) for 10 minutes at 4° C. The supernatant
was removed and the bacteria pellets were resuspended in ice-cold PBS (150 mM NaCl,
16 mM Na2 HPC>4 , 4 mM NaEhPO^ pH 7.3) and then incubated on ice for 10 minutes.
The resuspended pellets were sonicated at 35 strokes and then clarified by centrifugation
at 8,000 rpm (7,700 x g) for 10 minutes at 4° C. The supernatant was transferred to a
clean tube and Triton X-100 was added to the final concentration as 1% using 20%
stock in PBS. The supernatant containing 1% Triton X-100 was incubated for 30
minutes on ice and centrifuged at 10,000 rpm (12,000 x g) for 10 minutes at 4° C. The
supernatant was then filtered with

0 .2

jaM filter. The filtrate was collected for column

purification using glutathione sepharose 4B-column. The column used according to the
manufacturer’s instruction. The column was drained to remove the 20 % ethanol
storage preservative and washed with 10 ml o f PBS twice. The column was equilibrated
with 20 ml o f PBS containing 1% Triton X-100. The filtrate was slowly loaded on the
column and drained off completely. The column was then washed with PBS. The
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proteins bound on the column were eluted by adding elution buffer (5 mM glutathione
in 50 mM Tris-HCl, pH 8.0) and each eluate (fraction) was collected in a final volume
o f 2 ml. The OD596 value of each eluate containing GST-ATF2 fusion proteins was
measured and the amount o f purified proteins was calculated. The existence of GSTATF2 fusion proteins was determined on a 10 % gel by a Coomasie staining. The
purified GST-ATF2 fusion proteins were used as a JNK-1 substrate for in-gel JNK-1
kinase assays to measure the activity of JNK-1 (see section 2.8.).
2.9. Immune-Complex Kinase Assay for Lyn
To measure the kinase activity of Lyn, immunocomplex kinase assays were
performed using acid-denatured enolase (see section 2.9.1.) as a general substrate of Lyn
kinase with [y-P32] ATP. Cell lysates (500 pg of solubilized proteins) from wild type
and mutant Flag-tagged lyn DNA-infected and puromycin selected NIH/3T3 cells (see
section 2.13.) were immunoprecipitated with 5 pg of anti-Lyn antibody at 4° C for 3
hours. The immunocomplexes were further incubated with protein A-sepharose beads
(20% v/v) for 2 hours and then centrifuged at 14,000 rpm (10,000 x g) for 5 minutes at
4° C. Following centrifugation, the supernatant was removed and the
immunocomplexes were washed with RIPA buffer [50 mM Tris-Cl (pH 7.4), 150 mM
NaCl, 1% (v/v) Nonidet P (NP)-40, 1 mM EGTA, 1 mM EDTA, 1 mM PMSF, 1 mM
NasVO,*, leupeptin (10 pg/ml), and aprotinin (10 pg/ml)]. The immunocomplexes were
washed with kinase reaction buffer [100 mM HEPES-NaOH (pH 7.2), 10 mM MnCL].
After removing the residual washing solution, the immunocomplexes were preincubated
in the same kinase reaction buffer for

10

minutes and then incubated in the same kinase

reaction buffer containing 9 pg o f acid-denatured enolase and 10 pCi [y-P32] ATP
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(3,000 Ci/mmol, 5 jj.Ci/fj.1). The kinase reaction was stopped by the addition of
Laemmeli buffer and boiled at 100° C to dissociate the immunocomplexes, centrifuged
at 14,000 rpm (10,000 x g) for 5 minutes at 4° C and the supernatant was loaded on 10%
SDS-polyacrylamide gel. Following electrophoresis, the gel was washed until the
radioactivity o f the solution became negligible. The washed gel was dried in a gel drier
at 80° C for 1 hour. The dried gel was exposed to Kodak X-ray film at RT. The extent
of incorporated y-P in enolase used as an assessment of Lyn kinase activity.
2.9.1. Preparation of Acid-Denatured Enolase
Five hundred micrograms of rabbit muscle enolase (3.2 pg/pl, Sigma) was
centrifuged at 14,000 rpm (10,000 x g) at 4° C for 5 minutes. The pellet was resuspended
in resuspension buffer [50 mM HEPES-NaOH (pH 7.0), 1 mM DTT, 1 mM MgCh] and
incubated for 1 hour on ice. The resuspended pellet was denatured in 50 mM NaOAcAcOH (pH 3.3) by incubating at 30° C for 5 minutes. The immunocomplex kinase assay
for Lyn (see section 2.9.) used about 9 pg of acid-denatured enolase per reaction.
2.10. In Vitro Transcription
Using in vitro transcription method, radiolabeled RNA probes (antisense) of
COX-2 and GAPDH were prepared for ribonuclease protection assay (see section 2.11.)
for the detection o f COX-2 and GAPDH mRNA (sense) from unstimulated and
stimulated RAW 264.7 cells. In vitro transcription was performed using MAXIscript™
kit (Ambion) and followed protocols recommended by the manufacturer. To linearize the
circular form of pOSML plasmid DNA containing fiill-lengths of mouse COX-2 or
GAPDH cDNA, the plasmids were incubated in reaction mixture [pOSML plasmids
containing COX-2 or GAPDH cDNA, 10 x reaction buffer (#3, GIBCO-BRL), and Not I
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at 37° C for 4 hours. To determine whether the linearization of circular plasmids by Not I
was complete, a portion of linearized plasmids was run on 1% agarose gel. After
determining complete linearization, the reaction mixture was heated to inactivate Not I at
65° C for 15 minutes. To purify the linearized plasmids, the reaction mixture was placed
in phenolxhloroform (1:1) mixtures and centrifuged at 8,000 x g at 4° C for 5 minutes.
The aqueous layer containing DNA was transferred to a 1.5 ml tube and an equal volume
of chloroform was added, followed centrifugation at 8,000 x g 4° C for 1 minute. The
aqueous layer was transferred to another 1.5 ml tube and both 1/10 volume of 3 M NaOAc
and 2 volume o f cold absolute ethanol were added and then incubated at - 20° C for 15
minutes, followed centrifugation at 12,000 x g for 15 minutes at 4° C. The supernatant
was removed and the pellet was washed with cold 75% ethanol. After centrifugation at
12,000 x g at 4° C for 5 minutes, the supernatant was removed and the DNA pellet was
dried. The dried DNA pellet was then resuspended in TE buffer (10 mM Tris-Cl, 1 mM
EDTA, pH 7.6). The final concentration of linearized and purified plasmids was
measured at OD26o- Complementary RNA (cRNA) probe was synthesized from linearized
plasmids by using a MAXIscript™ kit. To generate radiolabeled RNA probes, the
following reaction mixture was assembled in order: linearized DNA template (COX-2 or
GAPDH, 1 pg), 200 mM DTT (1 pi), 10 mM ATP (1 pi), 10 mM CTP (1 pi), 10 mM
GTP (1 pi), 10 x Transcription buffer (2 pi), RNase inhibitor (1 pi), 0.1 M UTP (0.05 pi),
[a-32P] UTP (5 pi, 400-800 Ci/mmol), T7 RNA polymerase (10 units/pl), RNase free
water. The reaction mixture was incubated at RT for 1 hour. To digest linearized DNA
templates, DNase I was added to the reaction mixture and incubated at 37° C for 15
minutes, followed by inactivation of DNase I by the addition of 0.2 M EDTA. The
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reaction mixture was loaded on a 5% acrylamide-8 M urea gel to separate radiolabeled
RNA probe of COX-2 or GAPDH. After electrophoresis, the gel was exposed to a Kodak
film and was developed. The film was overlaid on the gel to mark the spots containing
radiolabeled RNA probes and the gel spots marked were excised. The radiolabeled RNA
probes were eluted from the excised gels by placing in the elution buffer at 37° C
overnight. A portion of each radiolabeled probe o f COX-2 or GAPDH from the eluate
was added to scintillation cocktail (Ecolite™, ICN) to measure the radioactivity o f COX-2
or GAPDH probes. The fractions having higher radioactivity were pooled and the
radioactivity of the pooled probes was measured.
2.11. Ribonuclease Protection Assay
The purpose of the ribonuclease protection assay (RPA) is to detect the level of
mRNA (sense) of COX-2 or GAPDH extracted from RAW 264.7 cells unstimulated and
stimulated with LPS or other agents for 4 hours. Using radiolabeled RNA probes
(antisense) o f COX-2 or GAPDH prepared by in vitro transcription method (see section
2.10.) described previously, ribonuclease protection assay kit (RPA H™, Ambion) was
used and the assay was basically performed according to the protocols recommended by
the manufacturer. Total cellular RNA from unstimulated and stimulated RAW 264.7
cells was extracted using TRIZOL reagent (GIBCO-BRL) and the concentration of total
cellular RNA was measured at OD260 - Two micrograms of total cellular RNA were
hybridized with both radiolabeled GAPDH (4 x 104 cpm) and COX-2 (8 x 104 cpm)
probes in a tube. To co-precipitate both sample mRNA and probe cRNA o f COX-2 or
GAPDH, NH 4 OAC (0.5 M) and absolute ethanol (2.5 volumes) were added to the tube
and incubated in - 20° C for 15 minutes and centrifuged at 14,000 rpm (10,000 x g) for
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15 minutes at 4° C. The ethanol supernatant was removed and the RNA pellets were
dissolved in hybridization buffer and immediately incubated at 90° C for 4 minutes to
denature or solubilize RNAs. The following hybridization reaction was carried out in a
45° C water bath for 18 hours to allow complete hybridization o f radiolabeled RNA
(antisense) probe and sample mRNA (sense) because of complementarity. After
hybridization, diluted RNase mixture was added to the tube and incubated at 37° C for
30 minutes to digest unprotected single-stranded or unhybridized RNAs. The RNase
inactivation and precipitation mixture was then added to the tube and further incubated
at - 20° C for 15 minutes. The tube was centrifuged at 14,000 rpm (10,000 x g) at 4° C
for 15 minutes. The supernatant was removed and the RNA pellets were resuspended in
loading buffer and heated at 90° C for 4 minutes to solubilize and denature RNA. The
heated RNA samples were run on 6% acrylamide gel containing 8 M urea. After
electrophoresis, the gel was covered with a piece of plastic wrap and exposed on an Xray film in the dark room. The ratio of radioactivity between the COX-2 and GAPDH
bands on the gel was determined by scanning the gel with Phosphorlmager (Molecular
Dynamics, California).
2.12. DNA Sequencing
We used DNA sequencing to verify whether the Flag-epitope sequence was
correct in wild type and mutant Flag-tagged lyn cDNAs o f the pBPSTRl retroviral
vector and the mutation in mutant lyn cDNA [Y508F, the tyrosine (Y) residue on 508
position in the C-terminal regulatory domain o f Lyn is replaced with phenylalanine (F)]
is also correct. The assay was basically performed according to a Sequenase™ QuickDenature™ Plasmid Sequencing Kit (United States Biochemical, USB) and the
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protocols recommended by the manufacturer. For alkali denaturation of double strand
DNA, 2 pg o f lyn cDNAs (wild type or mutant) were incubated in 3 pi of alkali solution
(2 M NaOH, 2 mM EDTA) at RT for 5 minutes. To neutralize the reaction, 3 pi of 2 M
NH4 CH 3 CO2 (pH 4.6) was added to the reaction tube and mixed by vortexing. Cold
absolute ethanol (- 20° C) was added and the tube was placed at - 20° C for 10 minutes.
The tube was centrifuged at 14,000 rpm (10,000 x g) at 4°C for 10 minutes. The
supernatant was removed and the DNA pellet was shortly dried at room temperature.
The dried DNA pellet was then resuspended in TE buffer (10 mM Tris-Cl, 1 mM
EDTA, pH 8.0). For annealing, the resuspended DNA (5 pi) was mixed with ddHjO (2
pi), annealing reaction buffer (2 pi), and primer (1 pi). The annealing reaction was
carried out at 65° C for 2 minutes and then cooled slowly to 35° C by removing the
heating iron template to room temperature. For radiolabeling, the annealed DNA
mixture (10 pi) was incubated in a mixture o f 0.1 M DTT (1 pi), diluted labeling
reaction buffer (2 pi), [35S] deoxyadenosine triphosphate (dATP) (0.7 pi), and diluted
sequenase polymerase (2 pi) at room temperature for 3 minutes. For radiolabeling
termination, 3.5 pi o f the radiolabeled reaction mixture was placed in 4 different tubes
containing 2.5 pi o f each termination mixture (A, G, C, and T) and the tubes were
incubated at 37° C for 5 minutes. After 5 minutes, each tube was mixed with 4 pi of
reaction stop solution and then heated at 75° C for 5 minutes. For DNA separation, the
heated DNA samples (3.2 pl/lane) were loaded onto a DNA sequencing gel and run
under 2,500 volts at 50-60° C for about 1.5-2.0 hours. After running, the gel was
overlaid by Whatmann 3MM paper in appropriate size and covered with a plastic wrap.
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The gel was then dried at 80° C for 1 hour in gel dryer. The dried gel was exposed on a
DNA sequencing film (Kodak) and developed.
2.13. Transfection, Infection, and Antibiotic Selection
The purpose of transfection, infection, and antibiotic selection is to determine
whether lyn cDNAs is correctly transfected and infected to cells, and to select only cells
expressing the products of lyn cDNAs under puromycin (antibiotic) treatment because
o f puromycin-resistance genes in the pBPSTRl vector. The overall purpose is to
examine whether overexpression o f mutant Lyn can induce the expression o f COX-2 in
cells. For the transfection of lyn cDNAs to cells, SuperFect reagent (Quiagen) was
applied. This reagent, having positive charges, can interact with the negative charges in
DNA and form DNA-SuperFect reagent complexes that make them permeable to the
cell membrane.
2.13.1. Transfection of lyn cDNAs to Phoenix Cells
Phoenix (d>NX) cells (a packaging cell line) were maintained in complete
DMEM containing 10% (v/v) heat-inactivated fetal bovine serum and 1% (v/v)
antibiotics (penicillin/streptomycin) at 37° C in 5% CCh/air mixtures. For transfection
experiment, about 0.5 ~ 1.0 x 106 ONX cells were plated into a 60-mm dish in 4 ml o f
complete DMEM containing 2 pg/ml of tetracycline the night before transfection.
Tetracycline was used to control the expression o f lyn cDNA because the transcription
o f any insert DNA in the pBPSTRl vector can be controllable by the presence or
absence o f tetracycline (Pear et al., 1993; Paulus et al., 1996). To prepare
DNA/SuperFect reagent complexes, 5 pg o f lyn cDNAs was diluted with DMEM
without containing serum and antibiotics to be a final volume of 150 pi in a 1.5-ml tube.
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SuperFect reagent (20 pi) was added to the tube containing lyn cDNAs and gently
mixed. The DNA/SuperFect reagent complexes were incubated for 10 minutes at room
temperature. At the same time, the culture media was removed from ONX cells and the
cells were washed with 4 ml of DMEM containing 1% penicillin/streptomycin twice.
After 10 minutes, 1 ml of DMEM supplemented with 10 % heat-inactivated FBS and
1% penicillin/streptomycin was added to the tube containing DNA/SuperFect reagent
complexes and gently mixed. The DNA/SuperFect reagent complexes were
immediately transferred to the ONX cells. After 3 hours post-transfection, the culture
media was removed and then washed with DMEM supplemented with 10 % heatinactivated FBS and 1% penicillin/streptomycin. Transfected ONX cells were then
grown in 4 ml o f DMEM supplemented with 10 % heat-inactivated FBS, 1%
penicillin/streptomycin, and 2 pg/ml of tetracycline for 21 hours. After 21 hours post
transfection, the culture media was removed and replaced with 2 ml of DMEM
supplemented with 10 % heat-inactivated FBS, 1% penicillin/streptomycin, and 2 pg/ml
of tetracycline for additional 24 hours. Meanwhile, 0.2 x 106 NIH/3T3 cells were plated
in 4 ml o f DMEM supplemented with 10 % heat-inactivated FBS, 1%
penicillin/streptomycin, and 2 pg/ml of tetracycline the night prior to infection.
2.13.2. Infection of NIH/3T3 Cells with Viral Particles Produced by Transfected
Phoenix Cells
After 48 hours post-transfection, the culture media containing infectious viral
particles produced by transfected ONX cells was transferred to a 15 ml tube and
centrifuged at 1,500 rpm for 5 minutes at room temperature. Following centrifugation,
the supernatant containing infectious viral particles was used to infect NIH/3T3 cells.
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For infection, the culture media from NIH/3T3 cells plated the night prior to infection
was removed and replaced with 2 ml o f DMEM supplemented with 10 % heatinactivated FBS, 1% penicillin/streptomycin, 8 pg/ml of polybrene (a polycationic
substance, Sigma), and 2 pg/ml of tetracycline. Polybrene was used to increase the
efficiency o f viral infection. The supernatant containing infectious viral particles was
added to NIH/3T3 cells and further incubated for 24 hours. After 24 hours post
infection, the culture media was removed and replaced with 4 ml of DMEM
supplemented with 10 % heat-inactivated FBS, 1% penicillin/streptomycin, and 2 pg/ml
o f tetracycline.
To determine whether wild or mutant type o f Flag-tagged Lyn proteins were
successfully expressed in transfected ONX cells, the ONX cells were grown in DMEM
supplemented with 10 % heat-inactivated FBS and 1% penicillin/streptomycin for 24
hours, washed with ice-cold PBS twice and lysed in RIPA buffer [50 mM Tris-Cl (pH
7.4), 150 mM NaCl, 1% (v/v) N P-40,1 mM EGTA, 1 mM EDTA, 1 mM PMSF, 1 mM
Na3 VC>4 , leupeptin (10 pg/ml), and aprotinin (10 pg/ml)] for 20 minutes on ice. Cell
lysates were used for western blotting analysis (see section 2.5.) or immunoprecipitation
(see section 2.6.) for Lyn or Flag detection using anti-Lyn antibody or anti-Flag
antibody.
2.13.3. Antibiotic (Puromycin) Selection for Stable Clones
After 24 hours post-infection, infected NIH/3T3 cells were grown in DMEM
supplemented with 10 % heat-inactivated FBS and 1 % penicillin/streptomycin in the
presence o f 2 pg/ml o f puromycin for several weeks. The pooled colonies and each
colony that survived in the presence o f puromycin during the selection periods were
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selected and grown for further studies. To determine the expression of wild or mutant
type of Flag-tagged Lyn proteins, about 5 ~ 10 x 106 NIH/3T3 cells (pooled colonies
and each colony) were grown in 4 ml of DMEM supplemented with 10 % heatinactivated FBS and 1 % penicillin/streptomycin for 24 hours. Cells were washed with
DMEM containing 1 % penicillin/streptomycin twice and then lysed in RIPA buffer [50
mM Tris-Cl (pH 7.4), 150 mMNaCl, 1% (v/v) N P-40,1 mM EGTA, 1 mM EDTA, 1
mM PMSF, 1 mM Na3VC>4 , leupeptin (10 pg/ml), and aprotinin (10 pg/ml)] for 20
minutes on ice. To examine the expression of Flag-tagged Lyn and COX-2, cell lysates
were used for western blot analysis (see section 2.5.) or immunoprecipitation (see
section 2.6.) using specific anti-Lyn, anti-Flag, or anti-COX-2 antibodies. Using these
same samples, the activity of overexpressed wild type and mutant Lyn kinase in infected
and selected NIH/3T3 cells was measured by an immunocomplex kinase assay (see
section 2.9.) using an acid-denatured enolase and [y-P32] ATP as substrates. The
enzymatic activity of COX-2 protein in infected and selected NIH/3T3 cells was
measured by radioimmunoassay (see section 2.7.).
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CHAPTER 3
RESULTS
3.1. Examination of the Involvement of LPS-induced Activation of MAPKs and
NF-kB on the Expression of COX-2 in LPS-stimulated RAW 264.7 Cells
3.1.1. LPS-induced Activation of MAPKs alone appears to be insufficient to
induce COX-2 Expression in LPS-stimulated RAW 264.7 Cells. The Activation of
NF-kB induced by LPS appears to be necessary for COX-2 Expression.
Using known activators of MAPKs, such as PMA, sorbitol, H2 O2 , or
combinations of these agents, we examined whether MAPK activation alone is
sufficient to induce the expression o f COX-2 in RAW 264.7 cells.
In addition to LPS (1 pg/ml), RAW 264.7 cells were treated with PMA (100
nM), sorbitol (0.4 M), H2 O2 (1 mM) or combinations of these agents [PMA (100 nM)
plus sorbitol (0.4 M) and PMA (100 nM) plus H2 O2 (1 mM)] for 30 minutes.
Solubilized samples were used for anti-phosphotyrosine immunoblotting analysis (see
section 2.4.) and western blotting analysis (see section 2.5.). RAW 264.7 cells were
also treated with the same agents used above for 4 hours, and total cellular RNA was
isolated and used for RPA (see section 2.11.) to measure the level o f COX-2 mRNA
expression. Cells were also treated with the same agents used above for 8 hours to
perform RIA (see section 2.7.) to measure the enzyme activity of COX-2 protein.
Figure 7A shows that LPS treatment (1 pg/ml, lane 2) resulted in tyrosine
phosphorylation o f ERK-1, ERK-2, and P38 MAP kinase as measured by antiphosphotyrosine immunoblotting analysis using anti-phosphotyrosine antibody (4G10),
which can recognize proteins containing phosphorylated tyrosine residues. PMA
treatment (100 nM, lane 3) caused strong tyrosine phosphorylation o f ERK-1 and ERK-
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Figure 7. Effects of LPS, PMA, sorbitol, H2 O 2 , or combinations of these agents on
the tyrosine phosphorylation of MAPKs, the expression of COX-2, and the
degradation of IkB-a in RAW 264.7 cells.
Lane 1, vehicle; lane 2, LPS (1 pg/ml); lane 3, PMA (100 nM); lane 4, sorbitol (0.4 M);
lane 5, PMA (100 nM) + sorbitol (0.4 M); lane 6, H20 2 (1 mM); lane 7, PMA (100 nM)
+ H20 2 (I mM).
(A) Anti-phosphotyrosine immunoblot analysis (panel A). RAW264.7 cells were
treated with the indicated agents for 30 minutes, and solubilized proteins were detected
by an anti-phosphotyrosine antibody (4G10). ERK-1-P, phosphorylated ERK-1; P38-P,
phosphorylated P38; ERK-2-P, phosphorylated ERK-2.
(B) JNK-1 western blot analysis (panel B). RAW 264.7 cells were treated with the
indicated agent for 30 minutes, and solubilized proteins were detected by an anti-JNK-1
antibody. JNK-1, nonphosphorylated JNK-1; JNK-1-P, phosphorylated JNK-1.
(C) Ribonuclease protection assay (RPA) (panel C). RAW264.7 cells were treated with
the indicated agents for 4 hours. Total cellular RNA was extracted by TRIZOL
reagents, and 2 pg o f total RNA were analyzed by RPA. The expression level o f mRNA
used as an internal control mRNA was compared with that o f COX-2 mRNA induced
by LPS.
(D) Radioimmunoassay (RLA) (panel D). RAW 264.7 cells were treated with the
indicated agent for 8 hours, and then arachidonic acid (30 pM) as an exogenous
substrate of COX-2 was added to the cells for 10 minutes. The conditioned culture
media was removed and analyzed by RIA to measure the amounts of PGE2produced by
COX-2. The amounts o f PGE2 measured by RIA were used as an assessment o f COX-2
activity.
(E) IkB-a western blot analysis (panel E). RAW 264.7 cells were treated with the
indicated agent for 30 minutes, and solubilized proteins were detected by an anti-IkB-a
antibody.
Panel A, B, and D are derived from Hwang, 1997.
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2. PMA treatment,however, did not cause tyrosine phosphorylation of P38 MAP
kinase. Sorbitol treatment (0.4 M, lane 4) induced strong tyrosine phosphorylation of
P38 MAP kinase and weak tyrosine phosphorylation of ERK-2. Sorbitol did not cause
tyrosine phosphorylation of ERK-1. H20 2 treatment (1 mM, lane 6) resulted in strong
tyrosine phosphorylation of ERK-1, ERK-2, and P38 MAP kinase. The treatments of
combinations of these agents, such as PMA plus sorbitol (lane 5) or PMA plus H20 2
(lane 7), caused strong tyrosine phosphorylation o f ERK-1, ERK-2, and P38 MAP
kinase. There was no tyrosine phosphorylation of ERK-1, ERK-2, and P38 MAP kinase
in the control (no treatment, lane 1). These results show that these agents, including
LPS, are apparent activators of ERK-1, ERK-2, or P38 MAP kinase in RAW 264.7
cells.
The tyrosine phosphorylation o f JNK-1 following treatment of these agents was
not detected by anti-phosphotyrosine antibody (4G10) in Figure 7A. To detect any
change of JNK-1 induced by these agonists, including LPS, JNK-i western blotting
analysis was performed using anti-JNK-1 antibody. The result of JNK-1 western blot
analysis (Figure 7B) indicated that the treatments o f LPS (lane 2), sorbitol (lane 4),
H20 2 (lane 6), PMA plus sorbitol (lane 5), or PMA plus H20 2 (lane 7) resulted in an
apparent electrophoretic mobility shift of JNK-1 in RAW 264.7 cells. However, PMA
treatment (lane 3) alone did not cause the electrophoretic mobility shift o f JNK-1,
similar to the control (no treatment, lane 1). These results show that LPS, sorbitol, and
H20 2 are strong activators o f JNK-1, but PMA is not an activator of JNK-1 in RAW
264.7 cells. The results o f RPA are shown in Figure 7C. Only LPS treatment (lane 2)
resulted in high induction o f COX-2 mRNA expression in RAW 264.7 cells. The
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treatments o f PMA (lane 3), sorbitol (lane 4), H2 O2 (lane 6), or combinations of these
agents, such as PMA plus sorbitol (lane 5) or PMA plus H2 O2 (lane 7), failed to induce
the induction of COX-2 mRNA expression in RAW 264.7 cells. The level o f GAPDH
mRNA expression, which was used as an internal control mRNA was constant in most
lanes as shown in Figure 7C, except in lane 4 (sorbitol). The reason for this lower level
o f GAPDH mRNA could be due to the loss of total cellular RNA or mRNA during
sample preparation or RPA procedures. The constant levels of GAPDH mRNA and
protein were observed in other RPA experiments and western blotting analyses using
the same treatment agent (data not shown).
The results of RIA are shown in Figure 7D. Only LPS treatment (lane 2)
resulted in high activity o f COX-2 protein as assessed by the amounts of PGE2
generated by LPS-induced COX-2 protein. LPS treatment caused about a 4.5-fold of
COX-2 protein activity over the control (lane 1). Other treatments including PMA (lane
3), sorbitol (lane 4), H2 O2 (lane 6), or combinations of these agents, such as PMA plus
sorbitol (lane 5) or PMA plus H2 O2 (lane 7), did not increase COX-2 protein activity.
These results indicate that high activity of COX-2 protein by LPS treatment results from
high level o f COX-2 mRNA expression shown in Figure 7C. Similarly, COX-2 protein
and COX-2 mRNA were not observed after treatment with PMA, sorbitol, H2 O2 , or
combinations of these agents.
Combined with data from Figure 7A to 7D, these results suggest the following
things: (1) activation of MAPKs by PMA, sorbitol, H 2 O2 , or combinations o f these
agents is insufficient to induce COX-2 mRNA expression in RAW 264.7 cells. (2)
LPS-induced activation o f MAPKs (ERK-I, ERK-2, P38 MAP kinase, and JNK-1)
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occurring within minutes is accompanied in LPS-induced expression of COX-2 mRNA
and protein occurring after several hours in RAW 264.7 cells stimulated with LPS. (3)
LPS-induced activation o f MAPKs (ERK-1, ERK-2, P38, and JNK-1) alone is likely to
be insufficient to induce the expression o f COX-2 mRNA and protein, suggesting that
there are additional signaling pathways activated by LPS leading to the expression of
COX-2 in LPS-stimulated RAW 264.7 cells.
To examine whether activation of NF-kB is involved in the expression of COX2, the same samples used for Figure 7A, and 7B were analyzed by an IkB-a immunoblot
analysis using an anti-IkB-a antibody. Since NF-kB activation correlates with rapid
proteolytic degradation o f IkB-a protein, this experiment reveals that the degradation o f
IkB-a protein by agonists indicates NF-kB activation. The results of IkB-a western blot
analysis are shown in Figure 7E. Only LPS treatment (lane 2) resulted in complete
degradation of IkB-a protein in RAW 264.7 cells, indicating NF-kB activation by LPS.
However, the treatments o f PMA (lane 3), sorbitol (lane 4), H2 O2 (lane 6), or
combinations of PMA plus sorbitol (lane 5) or PMA plus H2 O2 (lane 7) did not induce
degradation o f IkB-a protein in RAW 264.7 cells.
These results indicate that LPS is a potent inducer o f NF-kB activation in RAW
264.7 cells, but PMA, sorbitol, H2 O2 , or combinations of these agents are not activators
o f NF-kB in RAW 264.7 cells. These results suggest that rapid activation o f NF-kB
induced by LPS within minutes is accompanied in the expression o f COX-2 occurring
after several hours in LPS-stimulated RAW 264.7 cells.
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3.1.2. Partial Inhibition of MAPKs (ERK-1, ERK-2, and P38) by PD98059 and
SB203580 caused Partial Suppression of COX-2 Expression in LPS-stimulated
RAW 264.7 Cells
MEK-1 and MEK-2 are the upstream activators that phosphorylate and activate
ERK-1 and ERK-2 in most cell types. PD98059 selectively inhibits the kinase activity
of MEK-1 and MEK-2 (Pang et al., 1995), leading to inactivation of ERK-1 and ERK-2.
Using PD98059, the current study examined whether inhibition of ERK-1 and ERK-2
causes the suppression of COX-2 expression in LPS-stimulated RAW 264.7 cells.
RAW 264.7 cells were pretreated with PD98059 in different concentrations (0,
1,10, 50,100, and 200 pM) for 1 hour, and washed with DMEM containing 1 %
antibiotic (penicillin/streptomycin) twice. Cells were then treated with 1 pg/ml of LPS
plus PD98059 in the same concentrations used in pretreatment for 30 minutes. Cell
lysates were analyzed by in-gel protein kinase assay to measure the kinase activity of
ERK-1 and ERK-2. For in-gel ERK-1 and ERK-2 kinase assay, myelin basic protein
(MBP) was used as a general exogenous substrate of ERK-1 and ERK-2 with [y-P32]
ATP. The extent of incorporated y-P32 in MBP by ERK-1 and ERK-2 was used as an
indication o f ERK-1 and ERK-2 kinase activity. Cells were also treated with LPS plus
PD98059 in the same concentrations used in in-gel ERK-1 and ERK-2 kinase assay for
8 hours to perform RIA in order to measure the amount o f PGE2 . The amount of PGE2
was used as an indication o f COX-2 protein activity. For RIA, 30 pM o f arachidonic
acid as an exogenous substrate o f COX-2 was added to cells incubated for 8 hours.
The results o f an in-gel kinase assay showed that LPS-induced kinase activity of
ERK-1 and ERK-2 was inhibited by PD98059 treatment in a concentration-dependent
manner in LPS-stimulated RAW 264.7 cells as assessed by the decreased extent of
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incorporated y-P32 in MBP by ERK-1 and ERK-2 (Figure 8A). The results o f RIA
showed that LPS-induced COX-2 enzyme activity was decreased by PD98059 treatment
in a concentration-dependent manner in LPS-stimulated RAW 264.7 cells as assessed
by the decreased amount of PGE 2 (Figure 8B). These results indicate that the inhibition
of LPS-induced activation of ERK-1 and ERK-1 by PD98059 treatment resulted in an
inhibition o f LPS-induced COX-2 enzyme activity, suggesting that LPS-induced
activation o f ERK-1 and ERK-1 appears to be in part involved in the regulation of LPSinduced COX-2 protein activity in RAW 264.7 cells.
However, the treatment of PD98059 did not affect LPS-induced tyrosine
phosphorylation of P38 MAP kinase as measured by anti-phosphotyrosine
immunoblotting analysis using an anti-P38 antibody (Figure 8C). Furthermore,
PD98059 treatments did not affect LPS-induced activation of JNK-1 as measured by an
JNK-1 western blotting analysis using anti-JNK-1 antibody (Figure 8D), and by an in
gel JNK-1 kinase assay using ATF2 as an exogenous substrate of JNK-1 with [y-P32]
ATP (Figure 8E). These results indicate that inhibition of LPS-induced activation of
ERK-1 and ERK-2 is independent from that of LPS-induced activation of P38 MAP
kinase or JNK-1 in LPS-stimulated RAW 264.7 cells. These observations lead to the
suggestion that inhibition of LPS-induced activation o f P38 and/or JNK-1 appears to be
involved in regulation o f COX-2 expression in LPS-stimulated RAW 264.7 cells.
SB203580, a pyridinyl-imidazole compounds, inhibits CSBP [CSAID (cytokinesuppressive anti-inflammatory drug) binding protein], which is identified as P38 MAP
kinase homologue (Lee et al., 1993). Using SB203580, the current study examined
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Figure 8. Inhibition of the ERK-1 and ERK-2 activity and reduction of PGE2
levels by PD98059 in RAW 264.7 cells.
(A) ERK-1 and ERK-2 in-gel kinase assay (panel A). RAW 264.7 cells were pretreated
with PD98059 in the indicated concentrations for 1 hour, and then stimulated with LPS
(1 pg/ml) plus PD98059 in the same concentrations as pretreatment for 30 minutes.
Solubilized proteins were analyzed by an in-gel kinase assay using myelin basic protein
(MBP) as a substrate o f ERK-1 and ERK-2 with [y-P32] adenosine triphosphate (ATP).
The extent of incorporated y-P32 in MBP was used as an assessment of the activity of
ERK-1 and ERK-2.
(B) Radioimmunoassay (RIA) (panel B). RAW 264.7 cells were treated with the
indicated agent for 8 hours, and then arachidonic acid (30 pM) as a substrate of COX-2
was added to the cells for 10 minutes. The conditioned culture media was removed and
analyzed by RIA to measure the amounts of PGE2 produced by COX-2. The amounts of
PGE2 measured by RIA were used as an assessment of COX-2 activity.
(C) Anti-phosphotyrosine immunoblot analysis (panel C) of the same samples used in
panel A using an anti-phosphotyrosine antibody (4G10). P38-P, phosphorylated P38.
(D) JNK-1 western blot analysis (panel D) of the same samples used in panel A using an
anti-JNK-1 antibody. JNK-1, nonphosphorylated JNK-1; JNK-l-P, phosphorylated
JNK-1.
(E) JNK-1 in-gel kinase assay (panel E). To measure JNK-1 kinase activity, the same
samples and procedures in panel A were used except the use o f ATF2 as a substrate o f
JNK-1 instead of MBP. The extent o f incorporated y-P32 in ATF2 was used as an
assessment of the activity o f JNK-1.
Panel B, C, and D are derived from Hwang, 1997.
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whether inhibition of P38 MAP kinase causes the suppression o f COX-2 expression in
LPS-stimulated RAW 264.7 cells. RAW 264.7 cells were pretreated with SB203580 in
different concentrations (0, 0.05,0.25,1.25, 6.25, 12.5, and 37.5 pM) for 1 hour, and
washed with DMEM containing 1 % antibiotic (penicillin/streptomycin) twice. Cells
were then treated with 1 pg/ml of LPS plus SB203580 in the same concentrations used
in pretreatment for 30 minutes. Cell lysates were analyzed by anti-phosphotyrosine
immunoblotting analysis after immunoprecipitation with an anti-P38 antibody. RAW
264.7 cells were also treated withl pg/ml of LPS plus SB203580 in different
concentrations (0,0.05, 0.25,1.25, 6.25,12.5, and 37.5 pM) for 8 hours to perform
COX-2 western blotting analysis to measure the level of COX-2 protein affected by
SB203580 treatment.
The results of anti-phosphotyrosine immunoblot analysis after P38
immunoprecipitation showed that LPS-induced tyrosine phosphorylation of P38 MAP
kinase was decreased by SB203580 treatment in a concentration-dependent manner in
LPS-stimulated RAW 264.7 cells (Figure 9A). The results of COX-2 western blot
analysis showed that LPS-induced COX-2 protein expression was decreased by
SB203580 treatment in a concentration-dependent manner in LPS-stimulated RAW
264.7 cells (Figure 9B). However, the level o f GAPDH protein, an internal control, was
not affected by SB203580 treatment in all lanes as shown in Figure 9B. These results
indicate that inhibition o f LPS-induced activation o f P38 MAP kinase by SB203580
treatment resulted in an inhibition o f LPS-induced COX-2 protein expression,
suggesting that LPS-induced activation o f P38 MAP kinase may contribute to the
regulation o f LPS-induced COX-2 protein expression in RAW 264.7 cells.
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Figure 9. Inhibition of tyrosine phosphorylation of P38 MAP kinase and partial
inhibition of COX-2 expression by SB203580 in RAW 264.7 cells.
(A) P38 immunoprecipitation and anti-phosphotyrosine immunoblot analysis (panel A).
RAW 264.7 cells were pretreated with SB203580 in the indicated concentrations for 1
hour, and then stimulated with LPS (1 pg/ml) plus SB203580 in the same
concentrations as pretreatment for 30 minutes. Solubilized proteins (500 pg) were
immunprecipitated with an anti-P38 antibody and the immunoprecipitates were detected
by an anti-phosphotyrosine antibody (4G10). P38-P, phosphorylated P38.
(B) COX-2 and GAPDH western blot analysis (panel B). RAW 264.7 cells were treated
with LPS (1 pg/ml) plus SB203580 in the indicated concentrations for 8 hours without
pretreatment, and then solubilized proteins were detected by anti-COX-2 and antiGAPDH antibodies in a same membrane.
(C) JNK-1 western blot analysis (panel C) o f the same samples used in panel A using an
anit-JNK-1 antibody. JNK-1, nonphosphorylated JNK-1; JNK-1-P, phosphorylated
JNK-1.
Panel A and B are derived from Hwang, 1997.
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3.1.3. The Inhibition of NF-kB Activation by Z-LLF-CHO caused the Suppression
of COX-2 Expression in LPS-stimulated RAW 264.7 Cells without Affecting LPSinduced Tyrosine Phosphorylation of MAPKs
DiDonato et al. (1995) used various multicatalytic protease complex (MPC)
inhibitors, including Z-LLF-CHO (benzyloxy-carbonyl-Leu-Leu-phenylalaninal), to
demonstrate that the degradation of IkB-a is required for NF-kB activation. Using ZLLF-CHO, the current study tested whether the inhibition of NF-kB results in the
suppression of COX-2 expression in LPS-stimulated RAW 264.7 cells.
A time course study with LPS (1 pg/ml) was performed to determine when LPS
treatment causes the maximal degradation o f IkB-a (an indication of NF-kB activation)
in RAW 264.7 cells. RAW 264.7 cells were treated without or with LPS for different
time periods (0, 1,5,10,20, 30, 60, or 120 minutes). RAW 264.7 cells were also
pretreated with Z-LLF-CHO in different concentrations (0, 1, 5, or 20 |^M) for 1 hour,
and then treated with LPS (1 jag/ml) plus Z-LLF-CHO in the same concentrations used
in pretreatment for 30 minutes. Cell lysates were analyzed by western blot analysis for
IkB-a using anti-IkB-a antibody.
The results o f IkB-a western blot analysis demonstrated a dramatic degradation
of IkB-a protein at 20 minute after LPS treatment. Maximal degradation of IkB-a
protein occurred at 30 minutes after LPS treatment in RAW 264.7 cells (Figure 10A).
However, the degradation o f IkB-a protein induced by LPS treatment was transient
because IkB-a protein was fully recovered at 60 minutes after LPS treatment. These
results suggest that LPS-induced NF-kB activation appears to be a rapid and transient
event in LPS-stimulated RAW 264.7 cells.
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Figure 10. Inhibition of LPS-induced degradation of IkB-a and LPS-induced
expression of COX-2 by Z-LLF-CHO in RAW 264.7 cells.
(A) IkB-a western blot analysis (panel A and B). For panel A, RAW 264.7 cells were
treated with LPS (1 pg/ml) for the indicated time periods, and solubilized proteins were
detected by an anti-IkB-a antibody. For panel B, RAW 264.7 cells were pretreated with
Z-LLF-CHO in the indicated concentrations for 1 hour, and then stimulated with LPS (1
|ig/ml) plus Z-LLF-CHO in the same concentrations as pretreatment for 30 minutes.
Solubilized proteins were detected by an anti-IkB-a antibody. IkB-a,
nonphosphorylated IkB-a; IkB-a-P, phosphorylated IkB-a.
(B) COX-2 and GAPDH western blot analysis (panel C). RAW 264.7 cells were treated
with LPS (1 |ig/ml) plus Z-LLF-CHO in the indicated concentrations for 8 hours
without pretreatment, and then solubilized proteins were detected by anti-COX-2 and
anti-GAPDH antibodies in a same membrane.
(C) Anti-phosphotyrosine immunoblot analysis (panel D) of the same samples used in
panel B using an anti-phosphotyrosine antibody (4G10).
Panel B and C are derived from Hwang, 1997.
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Figure 10B showed that LPS-induced NF-kB activation (as assessed by degradation of
IkB-a protein) was inhibited by Z-LLF-CHO treatment in a concentration-dependent
manner in LPS-stimulated RAW 264.7 cells. The inhibition of LPS-induced NF-kB
activation by Z-LLF-CHO treatment resulted in the inhibition of LPS-induced COX-2
protein expression in a concentration-dependent manner in LPS-stimulated RAW 264.7
cells (Figure IOC). These results suggest that LPS-induced NF-kB activation may be
involved in LPS-induced COX-2 expression in RAW 264.7 cells.
Z-LLF-CHO treatment, however, did not affect LPS-induced tyrosine
phosphorylation of ERK-1, ERK-2, and P38 MAP kinase as measured by antiphosphotyrosine immunoblot analysis (Figure 10D), suggesting that inhibition of LPSinduced NF-kB activation is independent from that of LPS-induced activation of
MAPKs (ERK-1, ERK-2, and P38 MAP kinase).
3.1.4. Both Inhibition of LPS-induced Activation of MAPKs and NF-kB by
Radicicol or Herbimycin A resulted in the Suppression of COX-2 Expression in
LPS-stimulated RAW 264.7 Cells
Radicicol is an inhibitor o f p60v'sre (Kwon et al., 1992) and Herbimycin A is a
protein tyrosine kinase (PTK) inhibitor (Fukazawa et al., 1991). Herbimycin A also
inhibits IL-la-induced NF-kB activation (Iwasaki et al., 1992). It has been
demonstrated that these PTK inhibitors suppress the expression o f COX-2 in LPSstimulated rat alveolar macrophages (Chanmugam et al., 1995) and RAW 264.7 cells
(Gang, 1996). Using Radicicol or Herbimycin A, we examined whether both inhibition
o f LPS-induced activation o f MAPKs and NF-kB result in the suppression of COX-2
expression in LPS-stimulated RAW 264.7 cells.
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RAW 264.7 cells were pretreated with different concentrations of Radicicol (0,
0.001, 0.1, or 1 (ig/ml) or Herbimycin A (0.5 |ig/ml) for 3 hours, and then treated with
LPS (1 fig/ml) plus Radicicol or Herbimycin A in the same concentrations used in
pretreatment for 30 minutes. Cell lysates were prepared and analyzed by in-gel kinase
assay for ERK-1, ERK-2 or JNK-l, western blot analysis, or immunoprecipitation. For
COX-2 western blot analysis, RAW 264.7 cells were also treated with LPS (1 pg/ml)
plus Radicicol or Herbimycin A for 8 hours.
Figure 11A showed that LPS-induced activation o f ERK-1 and ERK-2 was
inhibited by Radicicol treatment in a concentration-dependent manner as measured by
in-gel ERK-1 & ERK-2 kinase assays using MBP as a general exogenous substrate. The
treatment o f 0.5 |ig/ml o f Herbimycin A weakly inhibited LPS-induced kinase activity
of ERK-1 and ERK-2 (Figure 11A). The same samples used in Figure 11A were also
immunoprecipitated with an anti-P38 antibody and then the immunoprecipitates were
analyzed by anti-phosphotyrosine immunoblot analysis with an anti-phosphotyrosine
antibody (4G10). Figure 1IB showed that LPS-induced tyrosine phosphorylation of P38
MAP kinase was inhibited by Radicicol and Herbimycin A in a concentration-dependent
manner. Figure 11C showed that LPS-induced activation of JNK-1 was inhibited by
Radicicol and Herbimycin A in a concentration-dependent manner as measured by JNK1 western blot analysis using an anti-JNK-1 antibody. These results indicate that
Radicicol or Herbimycin A inhibit LPS-induced activation o f MAPKs (ERK-1, ERK-2,
P38 MAP kinase, or JNK-1) in RAW 264.7 cells.
Figure 1 ID showed that LPS-induced degradation o f IkB-a was also inhibited
by Radicicol and Herbimycin A as measured by IkB-a western blot analysis with an
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Figure 11. Inhibition of LPS-induced activation of MAPKs, degradation of IkBa , and expression of COX-2 by Radicicol and Herbimycin A in RAW 264.7 cells.
(A) ERK-1 and ERK-2 in-gel kinase assay (panel A). RAW 264.7 cells were pretreated
with Radicicol and Herbimycin A in the indicated concentrations for 3 hours, and then
stimulated with LPS (1 pg/ml) plus these inhibitors in the same concentrations as
pretreatment for 30 minutes. Solubilized proteins were analyzed by an in-gel kinase
assay using myelin basic protein (MBP) as a substrate o f ERK-1 and ERK-2 with [y-P32]
adenosine triphosphate (ATP). The extent o f incorporated y-P32 in MBP was used as an
assessment of the activity of ERK-1 and ERK-2.
(B) P38 immunoprecipitation and then anti-phosphotyrosine immunoblot analysis
(panel B). Solubilized proteins (500 pg) used in panel A were immunprecipitated with
an anti-P38 antibody and then the immunoprecipitates were detected by an antiphosphotyrosine antibody (4G10). P38-P, phosphorylated P38.
(C) JNK-1 western blot analysis (panel C) of the same samples used in panel A using an
anit-JNK-1 antibody. JNK-1, nonphosphorylated JNK-1; JNK-1 -P, phosphorylated
JNK-1.
(D) IkB-a western blot analysis (panel D) o f the same samples used in panel A using an
anti-IkB-a antibody.
(E) COX-2 and GAPDH western blot analysis (panel E). RAW 264.7 cells were treated
with LPS (1 pg/ml) plus these inhibitors in the indicated concentrations for 8 hours
without pretreatment, and then solubilized proteins were detected by anti-COX-2 and
anti-GAPDH antibodies in a same membrane.
Panel A, B, C, D, and E are derived from Hwang, 1997.

79

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

LPS
(1 ng/ml)
Radicicol
(fig/ml)
Herbimycin A
(Pg/ml)

+

+

+

0.001 0.01

+

+

0.1

i

+

0.5
kDa
-53

Panel A

ERK-1
ERK-2

-49
Panel B
P38-P

-49
-JNK-l-P
-JNK-2

Panel C

-49
^_IkB -a

Panel D

-77
Panel E

^-COX-2

v 'V., H-' CKn-GAPDH

80

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

anti-IkB-a antibody. This result indicates that Radicicol or Herbimycin A inhibit NFkB activation by blocking LPS-induced degradation of IkB-a protein in RAW 264.7
cells. Figure 1 IE showed that the expression of COX-2 in LPS-stimulated RAW 264.7
cells was inhibited by the treatment o f Radicicol and Herbimycin A as measured by
COX-2 western blot analysis.
These results indicate that both inhibition of MAPKs and NF-kB by Src PTK
inhibitors such as Radicicol and Herbimycin A resulted in the suppression of COX-2
expression in LPS-stimulated RAW 264.7 cells. These results suggest that LPS-induced
activation o f MAPKs and NF-kB may be involved in LPS-induced COX-2 expression in
RAW 264.7 cells.
3.2. Examination of the Role of Lyn on COX-2 Expression
3.2.1. Overexpression of Mutant Lyn results in High Expression of COX-2 in
NIH/3T3 Cells Transfected with Mutant lyn cDNA
It has been demonstrated that Radicicol treatment inhibits the expression of
COX-2 as well as the tyrosine phosphorylation and protein level of Lyn in LPSstimulated rat alveolar macrophages (Chanmugam et al., 1995). Lyn is one of Srcfamily protein tyrosine kinases (PTKs) and predominantly expressed in macrophages.
This observation suggests that Src-family PTKs may play an important role in LPSmediated signaling pathways leading to the expression of COX-2 in LPS-stimulated
macrophages.
Xie et al. (1991) have reported that the expression of many immediate early
genes, including COX-2 gene, are induced in Rous sarcoma virus (RSV)-infected
chicken embryo fibroblasts (CEF) in which v-Srcp60 was constitutively overexpressed.
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v-Src is a mutant that one amino acid (tyrosine) at the C-terminal regulatory domain in
c-Src protein was mutated with another amino acid (phenylalanine). It suggests that
COX-2 expression be induced by an amino acid change at the C-terminal regulatory
domain in other Src-family PTKs.
Using wild type lyn DNA and mutant lyn DNA in which the tyrosine residue at
the C-terminal regulatory domain of Lyn was replaced with phenylalanine, the current
study examined whether overexpression o f mutant Lyn alone induces COX-2 expression
in mutant lyn DNA-transfected NIH/3T3 cells.
After transfection, the expression level of Lyn was determined in wild type and
mutant lyn DNA-transfected cells. Figure 12A showed that wild type (lane 2) and
mutant Lyn (lane 3) were highly expressed in <$NX cells as measured by Lyn western
blot analysis. There was no expression of Lyn in the control (pBPSTRl vector alone,
lane 1) as shown in Figure 12A. Because o f the attached Flag DNA sequence encoding
8 amino acids (Asp-Tyr-Asp-Asp-Asp-Asp-Lys) at the C-terminus of lyn DNA cloned
in pBPSTRl vector, Lyn is expressed as a Lyn-Flag (epitope) fusion protein in
transfected cells. Anti-Flag antibody was applied to detect the expression o f Flagtagged Lyn and to avoid the detection of any endogenous Lyn protein present in cells.
Figure 12B showed that the expression of Flag was determined by an anti-Flag antibody
in wild type (lane 2) and mutant Lyn (lane 3) in <DNX cells, whereas there was no Flag
expressed in the control (pBPSTRl vector alone, lane 1). These results indicate that lyn
DNAs were appropriately transfected to ONX cells. Figure 12C and 12D showed that
the high expression o f wild type (lane 2) and mutant (lane 3) Flag-tagged Lyn p56 was
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Figure 12. Detection of the expression of wild type and mutant Flag (epitope)tagged Lyn kinases in transfected Phoenix cells and infected NIH/3T3 cells with
wild type and mutant lyn cDNA.
(A) Lyn or Flag western blot analysis (panel A, B, C, and D). For panel A, Phoenix
cells were transfected with a retroviral expression vector pBPSTRl alone, or pBPSTRl
vectors containing wild type and mutant Flag-tagged lyn DNA. After 48 hour post
transfection, the culture media containing infectious viral particles produced by Phoenix
cells was removed, filtered, and used to infect NIH/3T3 cells. Phoenix cells were lysed
and solubilized proteins were detected by an anti-Lyn antibody. L ynp56, 56 kDa form of
L ynp53/56. For panel B, the same samples used in panel A were detected by an anti-Flag
antibody. For panel C, NIH/3T3 cells were infected with viral particles for 24 hours,
and selected in the presence o f an antibiotic puromycin (2 pg/ml). Selected NIH/3T3
cells were lysed and solubilized proteins were detected by an anti-Lyn antibody. For
panel D, the same samples used in panel C were detected by an anti-Flag antibody.
Lane 1, pBPSTRl vector alone; lane 2, wild type Flag-tagged lyn DNA-pBPSTRl; lane
3, mutant Flag-tagged lyn DNA-pBPSTRl.
(B) Flag immunoprecipitation and then Lyn western blot analysis (panel F). Samples
used in panel C were immunoprecipitated with an anti-Flag antibody and then the
immunoprecipitates were detected by an anti-Lyn antibody. Lane 1, pBPSTRl vector
alone; lane 2, wild type Flag-tagged lyn DNA-pBPSTRl; lane 3, mutant Flag-tagged lyn
DNA-pBPSTRl.
(C) Immune-complex Lyn kinase assay (panel F). The same samples used in panel C
were immunoprecipitated with an anti-Lyn antibody, and the immunoprecipitates were
analyzed by an immune-complex kinase assay using an acid-denatured enolase (9
pg/reaction) as a general substrate of Src kinases with [y-P32] (10 pCi/reaction). The
extent of incorporated y-P32 in enolase was used as an assessment of Lyn kinase activity.
Lyn-P, phosphorylated Lyn; enolase-P, phosphorylated enolase. Lane 1, wild type Flagtagged Lyn in the presence o f enolase; lane 2, wild type Flag-tagged Lyn in the absence
o f enolase; lane 3, mutant Flag-tagged Lyn in the presence o f enolase; lane 4, mutant
Flag-tagged Lyn in the absence o f enolase.
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determined by anti-Lyn or anti-Flag antibodies in infected NIH/3T3 cells, respectively.
Figure 12E confirmed the high expression of wild type (lane 2) and mutant (lane 3)
Flag-tagged Lyn p56 in infected NIH/3T3 cells by Lyn western blotting analysis after
immunoprecipitation with anti-Flag antibody.
After determining the high expression o f wild type and mutant L ynp56 in
infected NIH/3T3 cells, the kinase activity of wild type and mutant L ynp56 was
determined by an immunocomplex kinase assay. The immunocomplex-Lyn kinase
assay was performed using the immunoprecipitates with an anti-Lyn antibody and

[y-

P32] ATP in the absence or presence o f acid-denatured enolase as a general exogenous
substrate o f Lyn. The extent o f incorporated y-P32 in L ynp56 was assessed as the degree
of autophosphorylation on tyrosine residue in L ynp56. The extent o f incorporated y-P32
in enolase by L ynp56 was assessed as an indication of Lyn kinase activity. Figure 12F
showed that the degree o f autophosphorylation o f wild type Lynp56 (lane 1-enolase, and
lane 2-no enolase) was much higher than that of mutant L ynp56 (lane 3-enolase, and
lane 4-no enolase) in infected NIH/3T3 cells. Figure 12F also exhibited that the more
autophosphorylated wild type Lynp56 (lane 1) showed increased phosphorylation of
enolase, whereas less autophophorylated mutant L ynp56 did not phosphorylate enolase,
suggesting less kinase activity o f mutant Lyn pS6. These results suggest that high
autophosphorylation o f wild type Lyn p56 might be resulted from high expression level
of wild type L ynp56, whereas less autophosphorylation o f mutant L ynp56 might be
resulted from low expression level o f mutant L ynp56.
Figure 13A and 13B showed that overexpression of mutant Lyn p56 (lane 3)
induced much higher expression o f COX-2 (about 4-fold) than that o f wild type Lyn p56
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Figure 13. High COX-2 expression and production of PGE2 levels induced by
overexpression of mutant Lyn kinase in N1H/3T3 cells.
(A) COX-2 western blot analysis and immunoprecipitation (panel A and B). For panel
A, infected and selected NIH/3T3 cells were lysed and solubilized proteins were
analyzed by COX-2 immunoblot. The same samples used in panel A were
immunoprecipitated with an anti-COX-2 antibody and then the immunoprecipitates
were analyzed by COX-2 immunoblot (panel B). Lane 1, pBPSTRl vector alone; lane
2, wild type Flag-tagged lyn DNA-pBPSTRl; lane 3, mutant Flag-tagged lyn DNApBPSTRl.
(B) Radioimmunoassay (RIA) (panel C). Infected and selected NIH/3T3 cells (about 1
x 106) were grown in DMEM supplemented with 1 % (v/v) penicillin/streptomycin and
10 % (v/v) heat-inactivated FBS for 24 hours, and then arachidonic acid (30 pM) as a
substrate of COX-2 was added to cells for 10 minutes. The conditioned media was
removed and analyzed by RIA to measure the amounts of PGE2 produced by COX-2.
The amounts o f PGE2 measured by RIA were assessed as an indication o f COX-2
activity. Lane 1, pBPSTRl vector alone; lane 2, wild type Flag-tagged lyn DNApBPSTRl; lane 3, mutant Flag-tagged lyn DNA-pBPSTRl.
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(lane 2) in infected N1H/3T3 cells as measured by COX-2 western blot analysis and
immunoprecipitation. These results indicate that overexpression of mutant Lynp56 is
sufficient to induce the expression of COX-2 in infected NIH/3T3 cells.
To determine whether high expression level of COX-2 induced by
overexpression of mutant Lynp56 reflects high COX-2 enzyme activity in infected
NIH/3T3 cells, RIA was performed to measure the amount of PGE2 produced by COX2. The amount of PGE2 was used as an indication o f COX-2 enzyme activity. Figure
13C showed that the highest production of PGE2 was detected in mutant lyn DNAtransfected NIH/3T3 cells (lane 3). This result indicates that a high expression level of
COX-2 protein induced by overexpression of mutant Lynp56 reflects a high COX-2
enzyme activity, leading to increased production o f PGE2 . Figure 13C also displayed
that there was no difference of COX-2 enzyme activity in the control (lane 1) and wild
type L ynp56 (lane 2). This result indicates that a low expression level of COX-2
detected in wild type lyn DNA-infected NIH/3T3 cells (Figure 13A, and 13B) might be
resulted from the basal level of COX-2 protein present in these cells or the result of
other effects, such as serum in the culture media.
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CHAPTER 4
DISCUSSION
A number of signaling pathways have been implicated in LPS responses in
macrophages. The mitogen-activated protein kinases [MAPKs; extracellular signalregulated kinases (ERKs), P38 MAP kinase, and c-jun N-terminal kinases (JNKs)],
nuclear factor kappa B (NF-kB), and Lyn kinase are known to be activated in the early
stages (within minutes) of LPS signaling pathways. The current study shows the
following: 1) LPS-induced activation of MAPKs and NF-kB may be involved in the
expression o f COX-2 in LPS-stimulated RAW 264.7 macrophages; 2) Overexpression
o f mutant L y n p56 results in high expression of COX-2 and high production of PGE2 in
mutant lyn DNA-transfected NIH/3T3 cells.
LPS treatment results in rapid phosphorylation of MAPKs; ERK-1, ERK-2, P38
MAP kinase (Weinstein et al., 1991, 1992; Han et al., 1993; Gang, 1996), and JNK
(Hambleton et al., 1996). It has been shown that the LPS-induced phosphorylation of
MAPKs reflects their kinase activities (Davis, 1994; Hambleton et al., 1996; Hwang et
al., 1997). Increased protein phosphorylation is a rapid LPS-activated signaling event
that may mediate release of arachidonic acid metabolites (e.g. PGE2 ) in LPS-stimulated
RAW 264.7 cells (Weinstein et al., 1991).
The expression o f COX-2 is selectively induced by LPS treatment after several
hours in rat alveolar macrophages (Lee et al., 1992; Chanmugam et al., 1995) and RAW
264.7 macrophages (Gang, 1996). Chanmugam et al. (1995) indicated that maximum
phosphorylation occurs much earlier than maximum expression o f COX-2 mRNA and
protein in LPS-stimulated rat alveolar macrophages. These observations suggest that
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rapid LPS-induced activation o f MAPKs (within minutes) may be relevant to LPSinduced expression of COX-2 after several hours in LPS-stimulated macrophages. In
the current study, it was first examined whether rapid LPS-induced activation of
MAPKs (particularly ERK-1, ERK-2, or P38 MAP kinase) might be involved in LPSinduced expression of COX-2 in RAW 264.7 cells.
MEK-1 and MEK-2 are the immediate upstream protein kinases that
phosphorylate and activate ERK-1 and ERK-2, respectively. PD98059 is an inhibitor of
phosphorylation and kinase activity o f MEK-1 and MEK-2 (Pang et al., 1995). Using
PD98059, the current study examined whether inhibition of ERK-1 and ERK-2 can
regulate COX-2 expression in LPS-stimulated RAW 264.7 cells.
PD98059 treatment that inhibited the kinase activity of ERK-1 and ERK-2
following LPS treatment in a concentration-dependent manner (Figure 8A) resulted in
partial reduction of PGE2 production in a concentration-dependent manner in LPSstimulated RAW 264.7 cells (Figure 8B). Similarly, PD98059 treatment caused partial
inhibition o f COX-2 expression in LPS-stimulated RAW 264.7 cells (Hwang et al.,
1997). This partial inhibition o f COX-2 protein expression following PD98059
treatment was correlated with the partial reduction o f PGE2 levels by PD98059
treatment in LPS-stimulated RAW 264.7 cells. These results suggest that inhibition of
ERK-1 and ERK-2 may be involved in the suppression o f COX-2 expression, which
leads to the partial inhibition of COX-2 enzyme activity and PGE2 production. The
treatment o f PD98059, however, does not affect LPS-induced tyrosine phosphorylation
o f P38 MAP kinase (Figure 8C) and LPS-induced electrophoretic mobility shift o f JNK1 (Figure 8D) following LPS stimulation in RAW 264.7 cells. These results suggest
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that the regulatory mechanism of P38 MAP kinase and/or JNK-1 is independent from
thatofERK-1 andERK-2.
The production o f inflammatory cytokines including interleukin 1 (IL-1) and
tumor necrosis factor (TNF) from LPS-stimulated human monocytic cell line (THP1) is
inhibited by a new series of pyridinyl-imidazole compounds. SB203580, one of
pyridinyl-imidazole compounds, inhibits the kinase activity of a cytokine-suppressive
anti-inflammatory drug (CSAID) binding protein, which is identified as a P38 MAP
kinase homologue (Lee et al., 1993). Recently, Guan et al. (1997) demonstrated that the
pharmacological inhibition o f P38 MAP kinase by SC68376, another inhibitor of P38
MAP kinase, results in the inhibition of cytokine-induced stimulation of COX-2 and
PGE2 production. This suggests that the signaling pathway o f P38 MAP kinase may be
one of the important signaling mechanisms modulating the expression o f COX-2 and
PGE2 production induced by various agonists including LPS. Using SB203580, we
tested whether the inhibition of P38 MAP kinase might result in the suppression of
COX-2 expression in LPS-stimulated RAW 264.7 cells.
SB203580 treatment that inhibited tyrosine phosphorylation o f P38 MAP kinase
following LPS stimulation (Figure 9A) also resulted in partial suppression of COX-2
protein expression in LPS-stimulated RAW 264.7 cells (Figure 9B). Similarly,
SB203580 treatment partially reduced PGE2 levels in LPS-stimulated RAW 264.7 cell
(Hwang et al., 1997). This change of COX-2 protein expression following SB203580
treatment was correlated with the partial reduction o f PGE2 production by SB203580
treatment in LPS-stimulated RAW 264.7 cells. These results indicate that the inhibition
o f P38 MAP kinase may be involved in the suppression o f COX-2 protein expression,
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which leads to the partial reduction of PGE2 levels. This suggests that P38 MAPK is an
important regulator in COX-2 expression by LPS in RAW cells. It is supported by the
recent results by Dean et al., (1999) in which COX-2 mRNA stability and transcription
in LPS-stimulated human monocytes is regulated by P38 MAPK using SB 203580.
Using SB 203580, Ridley et al., (1997) also demonstrated the regulatory role of P38
MAPK on COX-2 expression induced by IL-1 in human fibroblasts. Using another P38
inhibitor, SC68376, Guan et al., (1997) suggested that p38 MAPK plays an important
role in IL-1 beta signaling mechanism, which mediates the up-regulation of
prostaglandin synthesis in glomerular mesangial cells.
As mentioned previously, LPS treatment rapidly activates MAPKs by a
phosphorylation event and the increased protein phosphorylation is a rapid LPSactivated signaling event that can mediate release o f arachidonic acid metabolites in
LPS-stimulated RAW 264.7 cells. Based on this information, it was reasonable to
postulate whether the LPS-induced activation of MAPKs alone might be sufficient to
lead to COX-2 expression in LPS-stimulated RAW 264.7 cells.
It has been shown that phorbol myristate acetate (PMA) is an activator o f ERK-1
and ERK-2, and sorbitol is an activator of P38 MAP kinase in mammalian cells (Han et
al., 1994). The treatment of hydrogen peroxide (H2 O2 ) results in phosphorylation of
several subfamilies o f MAPKs. Using these known activators o f MAPKs, the current
study further examined whether the activation of MAPKs alone might be sufficient to
induce COX-2 expression and PGE2 production in RAW 264.7 cells.
The treatment of PMA, sorbitol, H2 O2 , or combinations o f these agents that
resulted in the phosphorylation o f MAPKs (Figure 1A and IB, lanes 3,4, 5,6, and 7,
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respectively) failed to induce COX-2 mRNA expression (Figure 7C) and PGE2
production (Figure 7D) in RAW 264.7 cells. However, LPS treatment results in high
phosphorylation of MAPKs (Figure 7A and 7B, lane 2) as well as high expression of
COX-2 mRNA (Figure 7C, lane 2) and high amounts of PGE2 levels (Figure 7D, lane 2)
in RAW 264.7 cells. Our results indicate that the LPS-induced activation of MAPKs
alone is insufficient to induce COX-2 expression and PGE2 production in LPSstimulated RAW 264.7 cells, suggesting that there are additional signaling pathways
activated by LPS stimulation in RAW 264.7 cells.
It has been known that LPS treatment activates NF-kB transcription factor that
leads to the induction of many immediate early gene expressions (Baeuerle, 1991). It
has been reported that a specific DNA sequence recognized by activated NF-kB, which
is called the cw-acting NF-kB element, is present in the promoter region o f COX-2 gene
(Fletcher et al., 1992; Inoue et a l, 1995; Kosaka et al., 1994; Sirois et al., 1993;
Yamamoto et al., 1995). Newton et al. (1997) demonstrated that in epithelial cells,
which play a major role in inflammation, pro-inflammatory cytokines, such as
interleukin (IL)-ip, rapidly induce NF-kB DNA binding and cause up-regulation of NFkB-dependent genes, including COX-2 gene. These observations suggest that the
activation o f NF-kB may be an additional signaling event activated by LPS, which leads
to COX-2 expression in RAW 264.7 cells.
In unstimulated or resting cells, NF-kB is sequestered in the cytoplasm through a
physical association with an inhibitor protein, IkB-a. The treatment o f cells with
extracellular stimuli, including LPS, IL-ip or TNF-a, results in the specific
phosphorylation o f two serine residues on IkB-a protein followed by the ubiquitination
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(Roff et al., 1996) and then the degradation o f this inhibitor protein by some proteases
(Thanos and Maniatis, 1995). The degradation o f IkB-a protein releases free and active
NF-kB, which then translocates from the cytoplasm to the nucleus and activates the
transcription o f specific target genes (DiDonato et al., 1995). Since the activation of
NF-kB correlates with a rapid proteolytic degradation o f IkB-a protein (Siebenlist et al.,
1994; DiDonato et al., 1995), our studies revealed that the degradation of IkB-a protein
induced by LPS indicates the activation o f NF-kB in RAW 264.7 cells. LPS treatment
at 30 minutes results in almost complete degradation of IkB-a protein in RAW 264.7
cells (Figure 7E, and 10A), indicating the release of active NF-kB. However, after 30
minute LPS stimulation, the protein levels of IkB-a are fully recovered to its basal level
before LPS treatment (Figure 10A). Our results indicate that the degradation of IkB-a
induced by LPS (or the activation of NF-kB induced by LPS) is a rapid and transient
event.
Recently, DiDonato et al. (1995) applied Z-LLF-CHO, which is a multicatalytic
protease complex (MPC) inhibitor, to demonstrate that the degradation of IkB-a is
required for the activation of NF-kB. Using Z-LLF-CHO as the NF-kB inhibitor, we
tested whether the inhibition of NF-kB activation might result in the inhibition of COX2 expression in LPS-stimulated RAW 264.7 cells.
Z-LLF-CHO treatment that blocked LPS-induced degradation of IkB-a in a
concentration-dependent manner (Figure 10B) also resulted in the suppression of COX2 expression in LPS-stimulated RAW 264.7 cells (Figure 10C). These results indicate
that the inhibition o f NF-kB may be involved in the suppression o f COX-2 expression in
LPS-stimulated RAW 264.7 cells. Our studies suggest that the activation o f NF-kB may
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be involved in the expression of COX-2 in LPS-stimulated RAW 264.7 cells. This view
is also supported by the findings that activators o f MAPKs, such as PMA, H2 O2 ,
sorbitol or a combination of these agents that failed to induce COX-2 mRNA expression
(Figure 7C) and PGE2 production (Figure 7D) and also did not induce the degradation
of IkB-a (the activation of NF-kB) (Figure 7E). Only LPS treatment resulted in the
activation o f NF-kB by the degradation of IkB-a in RAW 264.7 cells (Figure 7E, and
10A). Z-LLF-CHO treatment, however, does not affect phosphorylation o f MAPKs in
LPS-stimulated RAW 264.7 cells (Figure 10D), indicating that the regulatory
mechanism of NF-kB is independent from that of MAPKs in RAW 264.7 cells.
Herbitnycin A is a protein tyrosine kinase (PTK) inhibitor (Fukasawa et a l,
1991) and interferes with IL-la-induced NF-kB activation in T and B cells (Iwasaki et
a l, 1992). Weinstein et a l (1992) demonstrated that Herbimycin A treatment inhibits
tyrosine phosphorylation o f MAPKs and reduces the release of arachidonic acid
metabolites, such as PGE2 . These observations imply that there may be a link between a
protein phosphorylation o f MAPKs and the production of arachidonic acid metabolites,
which are major products by COX. Radicicol is an inhibitor of v-Srcp60 PTK (Kwon et
a l, 1992). As noted previously, Radicicol and Herbimycin A inhibit the expression of
COX-2 in LPS-stimulated rat alveolar macrophages (Chanmugam et al., 1995; Feng et
a l, 1997) and RAW 264.7 cells (Gang, 1996). Previous results in this dissertation study
have also suggested that the activation of MAPKs and NF-kB may be involved in the
expression o f COX-2 in LPS-stimulated RAW 264.7 cells. Using Radicicol and
Herbimycin A, we examined whether both inhibition o f MAPKs and NF-kB might
result in the inhibition o f COX-2 expression in LPS-stimulated RAW 264.7 cells.
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Results by Gang (1996) demonstrated that Radicicol and Herbimycin A
treatment resulted in the inhibition o f LPS-induced tyrosine phosphorylation o f MAPKs
(ERK-1, ERK-2, and P38 MAP kinase) in LPS-stimulated RAW 264.7 cells. Similarly,
our results showed that the treatment of Radicicol and Herbimycin A resulting in
inhibition of activation of LPS-induced tyrosine phosphorylation, activation of MAPKs
(ERK-1, ERK-2, P38 MAP kinase, and JNK-1) and NF-kB also caused the inhibition of
COX-2 expression in LPS-stimulated RAW 264.7 cells (Figure 11A to 1IE). The
current results demonstrate that both LPS-induced activation of MAPKs and NF-kB
appears to be necessary for the expression o f COX-2 in LPS-stimulated RAW 264.7
cells.
Several Src-family PTKs, in association with cell surface receptor proteins,
participate in normal signaling pathways in hemopoietic cells, including monocytes and
macrophages (Bolen et al., 1992). The major cell surface receptor for LPS on
macrophages is CD14, a 55-kDa glycosyl-phosphatidylinositol (GPI)-anchored
membrane protein (Han et al., 1993; Kielian et al., 1995). Three members o f Src-family
PTKs, Lyn, Hck, and Fgr, are strong candidates for the primary signal transducers of
LPS responses (Meng et al., 1997). All three o f these kinases are rapidly activated
following LPS treatment. It has been reported that a portion of intracellular L ynp53/56,
which is one o f 9 Src-family PTKs, directly co-associates with CD 14 in human
monocytes (Stefanova et al., 1993). These observations suggest that Src-family PTKs
as upstream activators play critical roles in LPS-initiated or LPS/CD14-mediated signal
transduction pathways in monocytes and macrophages. So far, the functional roles of
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Src-family PTKs on the expression o f COX-2 in LPS-stimulated RAW 264.7 cells is not
clearly understood.
It has been demonstrated that both tyrosine phosphorylation and expression level
of Lynp53/56 was specifically inhibited by a PTK inhibitor Radicicol, which inhibits the
expression of COX-2 in LPS-stimulated rat alveolar macrophages (Chanmugam et al.,
1995). This observation implicates Src-family PTKs as upstream activators in LPS
signaling pathways, which leads to COX-2 expression in macrophages.
Xie et al. (1991) reported that many immediate early gene expressions, including
COX genes, are induced in Rous sarcoma virus (RSV)-infected chicken embryo
fibroblasts (CEF) in which v-Srcp60 was constitutively expressed. This observation
suggests a critical role of the tyrosine residue at the C-terminal regulatory domain in
regulating Src kinase activity and also implies the induction of many immediate early
gene expressions by Src-family kinases by a single amino acid change. As noted
previously, both tyrosine phosphorylation and expression level of Lyn kinase were
specifically inhibited by Radicicol treatment, which causes the suppression of COX-2
expression in LPS-stimulated rat alveolar macrophages (Chanmugam et al., 1995).
These observations implicated Lyn kinase in LPS signaling pathways leading to COX-2
expression in macrophages. Based on these observations, we tested whether
overexpression o f mutant Lyn might result in the induction of COX-2 expression in
mutant lyn DNA-transfected NIH/3T3 cells.
The two isoforms of Lynp53/56, which are derived from a single gene by
alternative splicing o f the RNA transcripts, differ in the presence or absence o f a 21amino acid sequence (Stanley et al., 1991). Because o f the complete coding sequence,

97

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

the 56 kDa isoform o f Lyn (Lynp56) was chosen for this gene transfection study. Flag
DNA sequence encoding 8 amino acids was placed at the C-terminus of the lyn DNA
insert in the retroviral vector pBPSTR.1 to avoid the detection of any endogenous Lyn
kinase not containing the Flag epitope. In addition to mutant lyn DNA encoding mutant
Lyn, vector DNA alone and wild type lyn DNA encoding normal Lyn was included in
transfection experiments.
The high expression of wild type and mutant Flag-tagged Lynp56 was detected
by anti-Lyn and anti-Flag antibodies in wild type and mutant lyn DNA-transfected $>NX
cells (Figure 12A, and 12B). Similarly, anti-Lyn or anti-Flag antibodies detected highly
expressed wild type and mutant Flag-tagged L ynp56 in wild type and mutant lyn DNAinfected NIH/3T3 cells (Figure I2C to 12E). These results indicate that wild type and
mutant lyn DNAs were appropriately transfected to <t>NX cells and they encoded a 56
kDa molecular weight of Lyn in transfected and infected cells.
Since the exact downstream substrate of Lyn kinase has not yet been identified,
an acid-denatured enolase was used as a general exogenous substrate in an
immunecomplex kinase assay to measure Lyn kinase activity. The extent of
incorporated y-P32 in enolase by wild type or mutant L ynp56 was assessed as an
indication of Lyn kinase activity. Our studies revealed that the extent of
autophosphorylation o f wild type LynpS6 is much higher than that of mutant Lyn p56
(Figure 12F). It is likely that wild type L ynpS6 doubly autophosphorylated at both the
397-tyrosine position in the protein kinase domain and the 508-tyrosine position in the
C-terminal regulatory domain. In contrast, mutant Lynp56 became only
monophosphorylated at the 397-tyrosine position in the protein kinase domain because
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of lack o f the 508-tyrosine in the C-terminal regulatory domain, resulting in a lower
phosphorylation level. Wild type L ynp56 phosphorylates enolase, whereas mutant Lyn
p56 does not phosphorylate enolase (Figure 12F), suggesting that only wild type L ynp56
had kinase activity. However, this may be the case only in an in vitro system because
enolase is not the downstream substrate o f Lyn in an in vivo system. Therefore, it
should be noted that this might be different in vivo system.
Surprisingly, the recent results by Donella-Deana et al. (1998) indicated that the
spontaneous autophosphorylation o f Lyn at both the protein kinase domain and the Cterminal regulatory domain causes different substrate specificity. According to these
researchers, upon autophosphorylation, Lyn becomes doubly autophosphorylated
molecules (at both tyrosine-397 and tyrosine-508) that possess an active catalytic
domain by their increased affinity toward peptide substrates. Donella-Deana et al.
(1998) also found that there is a novel conformation of Lyn that is catalytically active
despite the presence of an intramolecular interaction between the phosphorylated
tyrosine residue at the C-terminal regulatory domain and the SH2 domain, and this
novel conformation appears to show a reduced oncogenic potential resulting from its
defective recognition o f a subset o f protein substrates whose targeting is mediated by
the SH2 domain o f Lyn. It also has been explained that while double
autophosphorylation o f Lyn stimulates the kinase activity o f Lyn toward peptide
substrates, it actually prevents the phosphorylation o f protein substrates by Lyn, such as
phospho-p50/HS 1 (hematopoietic-lineage cell specific protein) (Yamanashi et al., 1993)
andp57/PDI (protein disulfide-isomerase) (Donella-Deana et al., 1996), whose
multiphosphorylation requires the accessibility o f the SH2 domain (Brunati et al., 1995;
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Ruzzene et al., 1996; Donella-Deana et al., 1996). Based on these observations, it may
be hypothesized that the autophosphorylation o f wild type Lynp56 occurred at both the
397-tyrosine position in the protein kinase domain and the 508-tyrosine position in the
C-terminal regulatory domain, and the double phosphorylated wild type Lyn p56 is likely
to have a higher affinity toward enolase that may not have the SH2 domain, resulting in
the increased phosphorylation of enolase. In contrast, mutant Lynp56 that is only
monophosphorylated at the 397-tyrosine position in the protein kinase domain may have
no affinity (or very low affinity) toward enolase because of the absence o f the SH2
domain in enolase, or a high affinity toward protein substrates containing the SH2
domain in infected NIH/3T3 cells.
Although the validity o f this hypothesis will require further testing, the current
transfection study found an interesting observation that overexpression o f mutant Lyn
p56 induces high COX-2 expression and PGE2 production in NIH/3T3 cells (Figure 13A
and 13C). It has been known that some intracellular effectors that are physically
associated with Lyn include phospholipase C-y2 (PLC-y2), phosphatidylinositol 3kinase (PI 3-K), and GTPase-activating protein (GAP) (Pleiman et al., 1993). SH2
interactions with tyrosine phosphoproteins are believed to play an important role in
regulating signal transduction. Since PLC-y2, GAP, and PI 3-K are potentially tyrosine
phosphorylated, their binding to Lynp56 may be mediated by the SH2 domain o f Lyn
(Pleiman et al., 1993).
Further studies are needed to determine which intracellular effector molecules
interact with mutant Lynp56 in infected NIH/3T3 cells by co-immunoprecipitation and
whether they are either directly or indirectly involved in the expression of COX-2 in
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infected NIH/3T3 cells. Further studies are also required to confirm that the high
induction of COX-2 expression from mutant lyn DNA-infected NIH/3T3 cells results
from overexpression of mutant Lynp56 alone by the approach of co-transfection of a
dominant-negative mutant Lyn DNA, which encodes a catalytically inactive Lyn kinase,
into the NIH/3T3 cells.
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CHAPTER 5
SUMMARY AND CONCLUSIONS
In this dissertation, the mechanism o f COX-2 expression induced by LPS in
RAW 264.7 cells was examined. The results can be summarized as follows. LPSinduced activation o f MAPKs (ERK-1, ERK-2, P38 MAP kinase, and JNK-1) might be
involved in the expression of COX-2 in LPS-stimulated RAW 264.7 cells. This was
supported by the results that the partial inhibition of LPS-induced activation of MAPKs
by inhibitors of MAPKs, such as PD98059 or SB203580, resulted in the partial
suppression o f COX-2 expression in LPS-stimulated RAW 264.7 cells. However, LPSinduced activation o f MAPKs alone appeared to be insufficient to induce the expression
of COX-2 in LPS-stimulated RAW 264.7 cells, suggesting that there are additional
signaling pathways activated by LPS, which leads to the expression o f COX-2. This
was supported by the observations that activators of MAPKs, such as PMA, sorbitol,
H2 O 2 , or combinations o f these agents failed to induce COX-2 expression in RAW
264.7 cells. NF-kB activation might be an additional signaling pathway activated by
LPS, which leads to COX-2 expression in RAW 264.7 cells. This was supported by the
results that acute LPS treatment caused the activation of MAPKs and also resulted in the
maximal degradation of IkB-a protein, thereby releasing active NF-kB. Activators of
MAPKs, such as PMA, sorbitol, H 2 O2 , or combinations of these agents that activated
MAPKs did not induce the degradation of IkB-a protein, indicating no activation of NFkB. No induction o f COX-2 expression by these agents in RAW 264.7 cells was
correlated with no activation o f NF-kB by these agents. LPS-induced activation o f NFkB appeared to be involved in the expression of COX-2 in LPS-stimulated RAW 264.7
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cells. This was supported by the observations that the inhibition of LPS-induced
activation o f NF-kB by the inhibitor o f NF-kB, Z-LLF-CHO, resulted in the suppression
of COX-2 expression in LPS-stimulated RAW 264.7 cells. Z-LLF-CHO treatment,
however, did not affect LPS-induced tyrosine phosphorylation o f MAPKs, indicating
that LPS-induced activation of NF-kB signaling pathway was different from LPSinduced activation of MAPKs signaling pathway. Both LPS-induced activation o f
MAPKs and NF-kB were likely to be involved in the expression of COX-2 in LPSstimulated RAW 264.7 cells. This was supported by the results that both inhibition of
LPS-induced activation of MAPKs and NF-kB by Radicicol and Herbimycin A
treatment caused the inhibition of COX-2 expression in LPS-stimulated RAW 264.7
cells. Finally, overexpression of mutant L ynp56 induced high COX-2 expression and
high production of PGE2 in mutant lyn DNA-transfected NIH/3T3 cells.
The current study concludes that LPS-induced COX-2 expression is likely to be
mediated via rapid LPS-induced activation o f MAPKs and NF-kB in LPS-stimulated
RAW 264.7 cells. Transfection data also demonstrate an interesting observation that
overexpression o f mutant Lynp56 leads to induce high COX-2 expression and high
production o f PGE2 in mutant lyn DNA-transfected NIH/3T3 cells.
Future research will have to confirm the expression o f COX-2 induced by
overexpression o f mutant Lynp56 in NIH/3T3 cells by co-transfection o f a dominantnegative mutant L ynp56. Future studies also will have to include the finding of
intermediate signaling molecules between mutant Lyn and COX-2 expression using the
NIH/3T3 cells. Further studies also will have to find whether overexpression o f mutant
Lyn kinase also induces COX-2 expression in macrophages or macrophage-like cell
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lines. Future studies also will have to determine the role o f each subfamily of MAPKs
and NF-kB on the expression of COX-2 and PGE2 production by transfection of each
DNA into RAW 264.7 cells. Any future studies also will have to find the functional
role o f Lyn on the activation of MAPKs and/or NF-kB in LPS signaling pathways. The
current study and further research may provide an insight to understand the LPS
signaling pathways leading to COX-2 expression and PGE2 production, which are
responsible for inflammation.
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APPENDIX

LIST OF ABBREVIATIONS
AA

Arachidonic acid

API

Activator protein 1

AP-1

A synonym of API

AP2

Activator protein 2

ATF2

Activating transcription factor 2.

ATP

Adenosine triphosphate

BMM

Bone marrow-derived macrophage

BSA

Bovine serum albumin

cAMP

Cyclic AMP

cDNA

Complementary DNA

CEFs

Chicken embryo fibroblasts

COX-1

Cyclooxygenase-1.

COX-2

Cyclooxygenase-2.

CPLA2

Cytosolic phospholipase A2

CRE

Cyclic AMP response element

cRNA

Complementary RNA

CSAIDs

Cytokine-suppressive anti-inflammatory drugs

Csk

C-terminal Src kinase

dATP

Deoxyadenosine triphosphate

DMEM

Dulbecco’s modified Eagle’s medium

DNA

Deoxyribonucleic acid
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DTT

Dithiothreitol

ECL

Enhanced chemiluminescence

EDTA

Ethylenediaminetetraacetic acid

EGF

Epithermal growth factor

EPA

Eicosapentaenoic acid

ERKs

Extracellular signal-regulated kinases

ERK-1

Extracellular signal-regulated kinase-1

ERK-2

Extracellular signal-regulated kinase-2

ERK-3

Extracellular signal-regulated kinase-3

ERK-4

Extracellular signal-regulated kinase-4

ERK-5

Extracellular signal-regulated kinase-5

FBS

Fetal bovine serum

GAP

GTPase-activating protein

GAPDH

Glyceraldehyde-3-phosphate dehydrogenase

Glu

Glutamate

Gly

Glycine

GPI

Glycosylphosphatidylinositol

GSH

Glutathione

GST

Glutathione S-transferase

GST-ATF2

Glutathione S-transferase-activating transcription factor 2

Hck

Hematopoietic cell kinase

HEPES

jV-2-hydroxyethylpiperazine-Ar’-2ethanesulphonic acid
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HIV

Human immunodeficiency virus

HPETEs

Hydroperoxy-5,8,12, 14-eicosatetraenoic acids

HS1

Hematopoietic-lineage cell specific protein

Ig

Immunoglobulin

IgG

Immunoglobulin G

IkB

Inhibitory kappa B

IkB-a

Inhibitory kappa B-a

IL

Interleukin

EL-1

Interleukin-1

IMP

Immunoprecipitattion

IPTG

Isopropyl-p-thio-galactopyranoside

JNKs

c-Jun N-terminal kinases

JNK-1

c-Jun N-terminal kinase-1

JNKK

c-Jun N-terminal kinase kinase

LB media

Luria Bertani media

LBP

LPS-binding protein

LPS

Lipopolysaccharide.

LTs

Leukotriens

Lyn

Lck/yes-related novel tyrosine kinase

MAPKs

Mitogen-activated protein kinases.

MAPKK-1

Mitogen-activated protein kinase kinase-1

MAPKK-2

Mitogen-activated protein kinase kinase-2

MBP

Myelin basic protein
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MEK-1

A synonym of MAPKK-1

MEK-2

A synonym of MAPKK-2

MEK-6

A synonym of MKK-6

MKK-1

A synonym of MAPKK-1

MKK-2

A synonym of MAPKK-2

MKK-3

Mitogen-activated protein kinase kinase-3

MKK-4

Mitogen-activated protein kinase kinase-4

MKK-6

Mitogen-activated protein kinase kinase-6

MPC

Multicatalytic protease complex

NF-kB

Nuclear factor-kappa B

NSAIDs

Nonsteroidal anti-inflammatory drugs

OD

Optical density

PBS

Phosphate-buffered saline

PBST

Phosphate-buffered saline-Tween 20

PDGF

Platelet-derived growth factor

PDI

Protein disulfide-isomerase

PDTC

Pyrolidinedithiocarbamate

PGs

Prostaglandins

PGE,

Prostaglandin Ei

pg e2

Prostaglandin E2

pg e2

Prostaglandin E2

pg g 2

Prostaglandin G2

pg h 2

Prostaglandin H2
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PGH

Prostaglandin H synthase

PGIs

Prostacyclins

PGS-2

Prostaglandin synthase-2

PI3-K

Phosphatidylinositol 3-kinase

PKC

Protein kinase C

PMSF

Phenylmethylsulfonicfluoride

PK.s

Protein kinases

PLC-y2

Phospholipase C-y2

PMA

Phorbol 12-myristate 13-acetate

PPs

Protein phosphatases

Pro

Proline

PTKs

Protein tyrosine kinases

PUFAs

Polyunsaturated fatty acids

PVDF

Polyvinylidene difluoride

RHD

Rel homology domain

RIA

Radioimmunoassay

RIPA

Radioimmunoassay precipitation buffer

RK

Reactivating kinase

RNA

Ribonucleic acid

ROIs

Reactive oxygen intermediates

RPA

Ribonuclease protection assay

RSK

Ribosomal S6 protein kinase

RSV

Rous sarcoma virus
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SAPKs'

Stress-activated protein kinases

SDS

Sodium dodecyl sulfate

SEK-1

Stress-activated kinase-1

Ser

Serine

SH-2

Src homology-2

SH-3

Src homology-3

SMC

Smooth muscle cell

SRE

Serum response element

TBS

Tris-buffered saline

TBST

Tris-buffered saiine-Tween 20

TCA

Trichloroacetic acid

TE (pH 8.0)

10 mM Tris-Cl, pH 8.0/lmM EDTA, pH 8.0

Thr

Threonine

TNF

Tumor necrosis factor

TNF-a

Tumor necrosis factor-a

TPA

12- Otetradecanoylphorbol-13-acetate

Tris

Tris(hydroxymethyl)aminomethane

TXs

Thromboxanes

Tyr

Tyrosine

UV

Ultraviolet

Z-LLF-CHO

Benzyloxy-carbonyl-Leu-Leu-phenylalaninal

135

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

VITA
The author was bom in Kangwon Province, Korea, on April 5, 1967. He
graduated from Chungju Un-Ho High School in February 1986. He entered the
Department of Food Science and Technology at Chungnam National University in
March 1986, and finished his Bachelor o f Science degree in February 1993. The author
served in the Korean Army for 3 years from 1988 to 1991.
The author began his graduate study at Louisiana State University in 1993.
Since 1993, he has worked as a graduate research assistant at Pennington Biomedical
Research Center at Louisiana State University. During the graduate program, he
obtained four publications after participating in many research projects regarding signal
transduction pathways leading to the expression of a mitogen/cytokine-inducible
cyclooxygenase-2, an enzyme that converts arachidonic acid to various prostaglandins,
which are pro-inflammatory mediators. The author is currently a candidate for the
degree o f Doctor o f Philosophy in the Department o f Food Science at Louisiana State
University.

136

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

DOCTORAL EXAMINATION AND DISSERTATION REPORT

Candidate:

Byeong Churl Jang

Major Field:

Food Science

Title of Dissertation:

Studies on Cyclooxygenase-2 Expression In
Lipopolysaccharide-Stimulated Macrophages

Approved:

Major Professor and ChalrmAnT

e Graduate School

EXAMINING COMMITTEE:

Co-Adviso

•

^<V ywuJ 1

Date of Fxamination:

April 5, 1999________

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

